U.S. patent application number 10/360186 was filed with the patent office on 2003-07-31 for inhibitors for use in hemostasis and immune function.
Invention is credited to Bishop, Paul D., Lasser, Gerald W., Sheppard, Paul O..
Application Number | 20030144208 10/360186 |
Document ID | / |
Family ID | 27400699 |
Filed Date | 2003-07-31 |
United States Patent
Application |
20030144208 |
Kind Code |
A1 |
Sheppard, Paul O. ; et
al. |
July 31, 2003 |
Inhibitors for use in hemostasis and immune function
Abstract
The present invention relates to polynucleotide and polypeptide
molecules for use as inhibitors in hemostasis and immune function.
Such inhibitors are members of the family of proteins bearing a
collagen-like domain and a globular domain. The inhibitors are
useful for promoting blood flow in the vasculature by reducing
thrombogenic and complement activity. The inhibitors are also
useful for pacify collagenous surfaces and modulating wound
healing.
Inventors: |
Sheppard, Paul O.; (Granite
Falls, WA) ; Lasser, Gerald W.; (Lynnwood, WA)
; Bishop, Paul D.; (Fall City, WA) |
Correspondence
Address: |
Brian J. Walsh
Patent Department
ZymoGenetics, Inc.
1201 Eastlake Avenue East
Seattle
WA
98102
US
|
Family ID: |
27400699 |
Appl. No.: |
10/360186 |
Filed: |
February 7, 2003 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10360186 |
Feb 7, 2003 |
|
|
|
09619740 |
Jul 19, 2000 |
|
|
|
6544946 |
|
|
|
|
09619740 |
Jul 19, 2000 |
|
|
|
09506855 |
Feb 17, 2000 |
|
|
|
6448221 |
|
|
|
|
09506855 |
Feb 17, 2000 |
|
|
|
09444794 |
Nov 22, 1999 |
|
|
|
09444794 |
Nov 22, 1999 |
|
|
|
09253604 |
Feb 19, 1999 |
|
|
|
Current U.S.
Class: |
514/9.4 ;
514/13.8; 514/14.9; 514/15.1; 514/17.7; 514/19.1; 514/19.3 |
Current CPC
Class: |
A61K 38/1709 20130101;
Y10S 514/929 20130101 |
Class at
Publication: |
514/12 |
International
Class: |
A61K 038/17 |
Claims
What is claimed is:
1. A method of promoting blood flow within the vasculature of a
mammal comprising administering to said mammal a therapeutically
effective amount of an adipocyte complement related protein; in a
pharmaceutically acceptable vehicle; whereby said adipocyte
complement related protein reduces thrombogenic and complement
activity within said vasculature.
2. A method according to claim 1 wherein said adipocyte complement
related protein comprises a polypeptide comprising a sequence of
amino acid residues that is at least 75% identical in amino acid
sequence to residues 26-281of SEQ ID NO: 2, wherein said sequence
comprises: Gly-Xaa-Xaa or Gly-Xaa-Pro repeats forming a collagen
domain, wherein Xaa is any amino acid, and a carboxy-terminal
globular portion.
3. A method according to claim 2, wherein said polypeptide
comprises a sequence of amino acid residues that is at least 90%
identical in amino acid sequence to residues 22-281 of SEQ ID NO:
2.
4. A method according to claim 2, wherein said polypeptide
comprises an amino acid sequence that is at least 90% identical in
amino acid sequence to residues 26-281 of SEQ ID NO: 2.
5. A method according to claim 3, wherein any differences between
said polypeptide and SEQ ID NO: 2 are due to conservative amino
acid substitutions.
6. A method according to claim 3, wherein said collagen domain
consists of 13 Gly-Xaa-Xaa repeats and 1 Gly-Xaa-Pro repeat.
7. A method according to claim 3, wherein said globular domain
consists of ten beta sheets.
8. A method according to claim 7, wherein said beta sheets are
associated with amino acid residues corresponding to 147-151,
170-172, 178-181, 191-203, 207-214, 219-225, 227-239, 244-250, and
269-274 of SEQ ID NO: 2.
9. A method according to claim 2, wherein said polypeptide
comprises residues 1-281 of SEQ ID NO: 2 or residues 1-281 of SEQ
ID NO: 44.
10. A method according to claim 2, wherein said polypeptide is
complexed to a second polypeptide to form a oligomer.
11. A method according to claim 10, wherein said polypeptides are
complexed by intermolecular disulfide bonds.
12. A method according to claim 11, wherein said oligomer is a
trimer.
13. A method according to claim 11 wherein said oligomer is a
hexamer.
14. A method according to claim 11 wherein said oligomer is an
18mer.
15. A method according to claim 1, wherein said polypeptide reduces
thrombogenic and complement activity by inhibition of the
complement pathway and inhibition collagen-mediated platelet
adhesion, activation or aggregation.
16. A method according to claim 1, wherein said polypeptide reduces
thrombogenic and complement activity by inhibition of the
complement pathway.
17. A method according to claim 1, wherein said polypeptide reduces
thrombogenic and complement activity by inhibition of
collagen-mediated platelet adhesion, activation or accretion.
18. A method according to claim 1, wherein said polypeptide reduces
thrombogenic and complement activity by inhibition of
collagen-mediated platelet aggregation.
16. A method according to claim 1, wherein said polypeptide is
administered prior to, during or following an acute vascular injury
in said mammal.
17. A method according to claim 16, wherein said injury is due to
vascular reconstruction.
18. A method according to claim 17, wherein said vascular
reconstruction comprises angioplasty, coronary artery bypass graft,
endarterectomy, microvascular repair or anastomosis of a vascular
graft.
19. A method according to claim 18, wherein said injury is due to
trauma, stroke or aneurysm.
20. A method of pacifying damaged collagenous tissues within a
mammal comprising administering to said mammal a therapeutically
effective amount of an adipocyte complement related protein;
whereby said protein renders the damaged collagenous tissue inert
towards complement activation, thrombotic activity or immune
activation
21. A method according to claim 20, wherein said adipocyte
complement related protein comprises a polypeptide comprising a
sequence of amino acid residues that is at least 75% identical in
amino acid sequence to residues 26-281 of SEQ ID NO: 2, wherein
said sequence comprises: Gly-Xaa-Xaa or Gly-Xaa-Pro repeats forming
a collagen domain, wherein Xaa is any amino acid, and a
carboxy-terminal globular portion.
22. A method according to claim 21, wherein said polypeptide
comprises a sequence of amino acid residues that is at least 90%
identical in amino acid sequence to residues 22-281 of SEQ ID NO:
2.
23. A method according to claim 21, wherein said polypeptide
comprises an amino acid sequence that is at least 90% identical in
amino acid sequence to residues 26-281 of SEQ ID NO: 2.
24. A method according to claim 22, wherein any differences between
said polypeptide and SEQ ID NO: 2 are due to conservative amino
acid substitutions.
25. A method according to claim 22, wherein said collagen domain
consists of 13 Gly-Xaa-Xaa repeats and 1 Gly-Xaa-Pro repeat.
26. A method according to claim 22, wherein said globular domain
consists of ten beta sheets.
27. A method according to claim 26, wherein said beta sheets are
associated with amino acid residues corresponding to 147-151,
170-172, 178-181, 191-203, 207-214, 219-225, 227-239, 244-250, and
269-274 of SEQ ID NO: 2.
28. A method according to claim 22, wherein said polypeptide
comprises residues 1-281 of SEQ ID NO: 2 or residues 1-281 of SEQ
ID NO: 44.
29. A method according to claim 22, wherein said polypeptide is
complexed to a second polypeptide to form a oligomer.
30. A method according to claim 29, wherein said polypeptides are
complexed by intermolecular disulfide bonds.
31. A method according to claim 29, wherein said oligomer is a
trimer.
32. A method according to claim 29 wherein said oligomer is a
hexamer.
33. A method according to claim 29 wherein said oligomer is an
18mer.
34. A method according to claim 20, wherein said damaged
collagenous tissues are due to injury associated with ischemia and
reperfusion.
35. A method according the claim 34, wherein said injury comprises
trauma injury ischemia, intestinal strangulation, or injury
associated with pre- and post-establishment of blood flow.
36. A method according to claim 20, wherein said polypeptide is
administered to a mammal suffering from cardiopulmonary bypass
ischemia and recesitation, myocardial infarction, or post-trauma
vasospasm.
37. A method according to claim 36, wherein said post-trauma
vasospasm comprises stroke, percutanious transluminal angioplasty,
endarterectomy, accidental vascular trauma or surgical-induced
vascular trauma.
38. A method of pacifying the surface of a prostatic biomaterial
for use in association with a mammal comprising administering to
said mammal a therapeutically effective amount of an adipocyte
complement related protein; whereby said polypeptide renders the
surface of said prosthetic biomaterial inert towards complement
activation, thrombotic activity or immune activation.
39. A method according to claim 38, wherein said adipocyte
complement related protein comprises a polypeptide comprising a
sequence of amino acid residues that is at least 75% identical in
amino acid sequence to residues 26-281 of SEQ ID NO: 2, wherein
said sequence comprises: Gly-Xaa-Xaa or Gly-Xaa-Pro repeats forming
a collagen domain, wherein Xaa is any amino acid, and a
carboxy-terminal globular portion.
40. A method according to claim 39, wherein said polypeptide
comprises a sequence of amino acid residues that is at least 90%
identical in amino acid sequence to residues 22-281 of SEQ ID NO:
2.
41. A method according to claim 39, wherein said polypeptide
comprises an amino acid sequence that is at least 90% identical in
amino acid sequence to residues 26-281 of SEQ ID NO: 2.
42. A method according to claim 40, wherein any differences between
said polypeptide and SEQ ID NO: 2 are due to conservative amino
acid substitutions.
43. A method according to claim 40, wherein said collagen domain
consists of 13 Gly-Xaa-Xaa repeats and 1 Gly-Xaa-Pro repeat.
44. A method according to claim 40, wherein said globular domain
consists of ten beta sheets.
45. A method according to claim 44, wherein said beta sheets are
associated with amino acid residues corresponding to 147-151,
170-172, 178-181, 191-203, 207-214, 219-225, 227-239, 244-250, and
269-274 of SEQ ID NO: 2.
46. A method according to claim 40, wherein said polypeptide
comprises residues 1-281 of SEQ ID NO: 2 or residues 1-281 of SEQ
ID NO: 44.
47. A method according to claim 39, wherein said polypeptide is
complexed to a second polypeptide to form a oligomer.
48. A method according to, claim 47, wherein said polypeptides are
complexed by intermolecular disulfide bonds.
49. A method according to claim 47, wherein said oligomer is a
trimer.
50. A method according to claim 47 wherein said oligomer is a
hexamer.
51. A method according to claim 47 wherein said oligomer is an
18mer.
52. A method of pacifying the surface of a prostatic biomaterial
according to claim 38, wherein the surface of said prostatic
biomaterial is coated with collagen or collagen fragments, gelatin,
fibrin or fibronectin.
53. A method of mediating wound repair within a mammal comprising
administering to said mammal a therapeutically effective amount of
an adipocyte complement related protein; whereby said polypeptide
enhances progression in wound healing.
54. A method according to claim 53, wherein said adipocyte
complement related protein comprises a polypeptide comprising a
sequence of amino acid residues that is at least 75% identical in
amino acid sequence to residues 26-281 of SEQ ID NO: 2, wherein
said sequence comprises: Gly-Xaa-Xaa or Gly-Xaa-Pro repeats forming
a collagen domain, wherein Xaa is any amino acid, and a
carboxy-terminal globular portion.
55. A method according to claim 54, wherein said polypeptide
comprises a sequence of amino acid residues that is at least 90%
identical in amino acid sequence to residues 22-281 of SEQ ID NO:
2.
56. A method according to claim 54, wherein said polypeptide
comprises an amino acid sequence that is at least 90% identical in
amino acid sequence to residues 26-281 of SEQ ID NO: 2.
57. A method according to claim 55, wherein any differences between
said polypeptide and SEQ ID NO: 2 are due to conservative amino
acid substitutions.
58. A method according to claim 55, wherein said collagen domain
consists of 13 Gly-Xaa-Xaa repeats and 1 Gly-Xaa-Pro repeat.
59. A method according to claim 55, wherein said globular domain
consists of ten beta sheets.
60. A method according to claim 59, wherein said beta sheets are
associated with amino acid residues corresponding to 147-151,
170-172, 178-181, 191-203, 207-214, 219-225, 227-239, 244-250, and
269-274 of SEQ ID NO: 2.
61. A method according to claim 55, wherein said polypeptide
comprises residues 1-281 of SEQ ID NO: 2 or residues 1-281 of SEQ
ID NO: 44.
62. A method according to claim 55, wherein said polypeptide is
complexed to a second polypeptide to form a oligomer.
63. A method according to claim 62, wherein said polypeptides are
complexed by intermolecular disulfide bonds.
64. A method according to claim 62, wherein said oligomer is a
trimer.
65. A method according to claim 62, wherein said oligomer is a
hexamer.
66. A method according to claim 62, wherein said multimer is an
18mer.
67. A method according to claim 62, wherein progression in wound
healing comprises reduction in inflammation, reduction in
fibroblast recruitment, wound retraction, or reduction in
infection.
68. A method for inhibiting platelet adhesion comprising
administering to a patient in need of such inhibition a
therapeutically effective amount of an adipocyte complement related
protein in a pharmaceutical acceptable vehicle.
69. A method for inhibiting platelet activation comprising
administering to a patient in need of such inhibition a
therapeutically effective amount of an adipocyte complement related
protein in a pharmaceutical acceptable vehicle.
70. A method for inhibiting platelet accretion comprising
administering to a patient in need of such inhibition a
therapeutically effective amount of an adipocyte complement related
protein in a pharmaceutical acceptable vehicle.
71. A method for minimizing vascular occlusion by increasing
patency time in a patient in need of such treatment comprising
administering an adipocyte complement related protein in a
pharmaceutically acceptable vehicle, wherein said adipocyte
complement related protein promotes blood flow.
72. A method according to claim 71, wherein said adipocyte
complement related protein is administered concurrently with, or
within an effective time period before, an acute vascular
injury.
73. A method according to claim 71 wherein said adipocyte
complement related protein is administered following an acute
vascular injury.
74. A method according to claim 71, wherein blood flow is increased
by inhibition of platelet adhesion, activation or accretion.
75. A method for inducing vasodilation within the vasculature of a
mammal comprising administrating to said mammal a therapeutically
effective amount of an adipocyte complement related protein; in a
pharmaceutically acceptable vehicle; whereby said adipocyte
complement related protein elicits a vasorelaxant response.
76. A method for protecting ischemic myocardium from reperfusion
injury comprising administering an adipocyte complement related
protein to a patient in need of such protection, wherein said
adipocyte complement related protein inhibits complement.
77. A method for mediating tumor metastasis comprising
administering an adipocyte complement related protein to a patient
in need of such inhibition, wherein said adipocyte complement
related protein mediates tumor cell binding to collagen.
78. A method for inhibiting platelet adhesion comprising
administering to a patient a therapeutically effective amount of a
formulation comprising: a polypeptide comprising amino acid
residues 26 to 281 of SEQ ID NO: 2 and; a pharmaceutical acceptable
vehicle.
79. The method of claim 78 wherein the polypeptide is SEQ ID NO:
2.
80. The method of claim 78 wherein the formulation is administered
prior to, during, or following an acute vascular injury.
81. The method of claim 80 wherein the formulation is administered
at or near the vascular injury site.
82. The method of claim 80 wherein the vascular injury is due to
vascular reconstruction.
83. The method of claim 82 wherein the vascular reconstruction
comprises angioplasty, coronary artery bypass graft,
endarterectomy, microvascular repair or anastomosis of a vascular
graft.
84. The method of claim 80 wherein the vascular injury is due to
trauma, stroke or aneurysm.
85. The method of claim 80 wherein the vascular injury is due to
plaque rupture or degradation of the vasculature.
86. The method of claim 80 wherein the vascular injury comprises
trauma injury ischemia, intestinal strangulation or injury
associated with pre- and post-establishment of blood flow.
87. The method of claim 78 wherein the patient suffers from
cardiopulmonary bypass ischemia and recesitation, diabetes,
atherosclerosis, disseminated intravascular coagulation, myocardial
infarction, or post-trauma vasospasm.
88. The method of claim 87 wherein the post-trauma vasospasm
comprises stroke, percutanious transluminal angioplasty, accidental
vascular trauma or surgical-induced vascular trauma.
89. The method of claim 78 wherein the formulation is administered
parenterally, orally, nasally, rectally, topically or
transdermally.
90. The method of claim 78 wherein the polypeptide is complexed to
a second polypeptide to form an oligomer.
91. The method of claim 90 wherein the-polypeptides are complexed
by intermolecular disulfide bonds.
92. The method of claim 91 wherein the oligomer is a trimer.
93. The method of claim 91 wherein the oligomer is a hexamer.
94. The method of claim 91 wherein the oligomer is an 18mer.
95. A method for inhibiting platelet activation comprising
administering to a patient a therapeutically effective amount of a
formulation comprising: a polypeptide comprising amino acid
residues 26 to 281 of SEQ ID NO: 2 and; a pharmaceutical acceptable
vehicle.
96. The method of claim 95 wherein the polypeptide is SEQ ID NO:
2.
97. The method of claim 95 wherein the formulation is administered
prior to, during, or following an acute vascular injury.
98. The method of claim 97 wherein the formulation is administered
at or near the vascular injury site.
99. The method of claim 97 wherein the vascular injury is due to
vascular reconstruction.
100. The method of claim 99 wherein the vascular reconstruction
comprises angioplasty, coronary artery bypass graft,
endarterectomy, microvascular repair or anastomosis of a vascular
graft.
101. The method of claim 97 wherein the vascular injury is due to
trauma, stroke or aneurysm.
102. The method of claim 97 wherein the vascular injury is due to
plaque rupture or degradation of the vasculature.
103. The method of claim 97 wherein the vascular injury comprises
trauma injury ischemia, intestinal strangulation or injury
associated with pre- and post-establishment of blood flow.
104. The method of claim 95 wherein the patient suffers from
cardiopulmonary bypass ischemia and recesitation, diabetes,
atherosclerosis, disseminated intravascular coagulation, myocardial
infarction, or post-trauma vasospasm.
105. The method of claim 104 wherein the post-trauma vasospasm
comprises stroke, percutanious transluminal angioplasty, accidental
vascular trauma or surgical-induced vascular trauma.
106. The method of claim 95 wherein the formulation is administered
parenterally, orally, nasally, rectally, topically or
transdermally.
107. The method of claim 95 wherein the polypeptide is complexed to
a second polypeptide to form an oligomer.
108. The method of claim 107 wherein the polypeptides are complexed
by intermolecular disulfide bonds.
109. The method of claim 108 wherein the oligomer is a trimer.
110. The method of claim 108 wherein the oligomer is a hexamer.
111. The method of claim 108 wherein the oligomer is an 18mer.
112. A method for inhibiting platelet accretion comprising
administering to a patient a therapeutically effective amount of a
formulation comprising: a polypeptide comprising amino acid
residues 26 to 281 of SEQ ID NO: 2 and; a pharmaceutical acceptable
vehicle.
113. The method of claim 112 wherein the polypeptide is SEQ ID NO:
2.
114. The method of claim 112 wherein the formulation is
administered prior to, during, or following an acute vascular
injury.
115. The method of claim 114 wherein the formulation is
administered at or near the vascular injury site.
116. The method of claim 114 wherein the vascular injury is due to
vascular reconstruction.
117. The method of claim 116 wherein the vascular reconstruction
comprises angioplasty, coronary artery bypass graft,
endarterectomy, microvascular repair or anastomosis of a vascular
graft.
118. The method of claim 114 wherein the vascular injury is due to
trauma, stroke or aneurysm.
119. The method of claim 114 wherein the vascular injury is due to
plaque rupture or degradation of the vasculature.
120. The method of claim 114 wherein the vascular injury comprises
trauma injury ischemia, intestinal strangulation or injury
associated with pre- and post-establishment of blood flow.
121. The method of claim 112 wherein the patient suffers from
cardiopulmonary bypass ischemia and recesitation, diabetes,
atherosclerosis, disseminated intravascular coagulation, myocardial
infarction, or post-trauma vasospasm.
122. The method of claim 121 wherein the post-trauma vasospasm
comprises stroke, percutanious transluminal angioplasty, accidental
vascular trauma or surgical-induced vascular trauma.
123. The method of claim 112 wherein the formulation is
administered parenterally, orally, nasally, rectally, topically or
transdermally.
124. The method of claim 112 wherein the polypeptide is complexed
to a second polypeptide to form an oligomer.
125. The method of claim 124 wherein the polypeptides are complexed
by intermolecular disulfide bonds.
126. The method of claim 125 wherein the oligomer is a trimer.
127. The method of claim 125 wherein the oligomer is a hexamer.
128. The method of claim 125 wherein the oligomer is an 18mer.
Description
REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part of U.S. patent
application Ser. No. 09/506,855, filed on Feb. 17, 2000, which is a
continuation-in-part of U.S. patent application Ser. No.
09/444,794, filed on Nov. 22, 1999, which is a continuation-in-part
of U.S. patent application Ser. No. 09/253,604, filed on Feb. 19,
1999, all three of which applications are pending.
BACKGROUND OF THE INVENTION
[0002] Injury to the blood vessels sets in motion a series of
events to repair the damage and control release of blood from the
vessel. This process is known as hemostasis. Platelets play an
early role in hemostasis by forming a thrombus or plug to
temporarily repair the vessel damage. Platelets normally do not
interact with the endothelium lining the vessel walls, but injury
to blood vessels, through accident or during surgical procedures,
may disrupt endothelial cells. Depending on the extent of the
injury, various subendothelial elements such as collagens, elastic
lamina or smooth muscle cells with associated fibrillar collagens
will be exposed to the flowing blood.
[0003] When the subendothelium is exposed following vessel injury,
platelets moving in the local blood flow interact with exposed
subendothelium matrix containing collagen and are slowed down.
Further interaction between receptors on the platelet surface and
the exposed collagen layer leads to platelet binding and activation
resulting in the arrest of local blood flow. The bound platelets
are activated and form aggregates with platelets in the passing
blood flow through the formation of fibrinogen-interplatelet
bridges (Moroi and Jung, Frontiers in Bioscience 3:719-28, 1998;
Barnes et al., Atherosclerosis XI, Jacotot et al., eds., Elsevier
Science, pp. 299-306, 1998 and Barnes et al., Curr. Opin. Hematol.
5:314-20, 1998).
[0004] The hemostatic response is graded and dependent on the
degree of injury to the blood vessel, the specific blood vessels
constituents exposed and the blood flow conditions in the injured
area (Rand et al., Thrombosis and Haemostasis 78:445-50, 1997).
Exposure of the subendothelium matrix (type VI collagen and von
Willebrand factor), such as during mild vascular injury, promotes a
low degree of adhesion and aggregation in areas with low blood flow
conditions. Injuries that result in a greater degree of vascular
trauma and exposure of additional vascular constituents, such as
the internal elastic lamina and elastin-associated microfibrils,
will stimulate the formation of stronger platelet aggregates.
Severe vascular trauma, exposing fibril collagens, provokes a
thrombotic platelet response, which protects the victim from
excessive loss of blood (Rand et al., ibid.).
[0005] Inhibitors of hemostasis would be useful for to increase
blood flow following vascular injury and to pacify collagenous
surfaces.
[0006] Complement factor C1q consists of six copies of three
related polypeptides (A, B and C chains), with each polypeptide
being about 225 amino acids long with a near amino-terminal
collagen domain and a carboxy-terminal globular region. Six triple
helical regions are formed by the collagen domains of the six A,
six B and six C chains, forming a central region and six stalks. A
globular head portion is formed by association of the globular
carboxy terminal domain of an A, a B and a C chain. C1q is
therefore composed of six globular heads linked via six
collagen-like stalks to a central fibril region. Sellar et al.,
Biochem. J. 274: 481-90, 1991. This configuration is often referred
to as a bouquet of flowers. Acrp30 has a similar bouquet structure
formed from a single type of polypeptide chain.
[0007] C1q has been found to stimulate defense mechanisms as well
as trigger the generation of toxic oxygen species that can cause
tissue damage (Tenner, Behring Inst. Mitt. 93:241-53, 1993). C1q
binding sites are found on platelets. Additionally complement and
C1q play a role in inflammation. The complement activation is
initiated by binding of C1q to immunoglobulins
[0008] Inhibitors of C1q and the complement pathway would be useful
for anti-inflammatory applications, inhibition of complement
activation and thrombotic activity.
[0009] The present invention provides such polypeptides for these
and other uses that should be apparent to those skilled in the art
from the teachings herein.
SUMMARY OF THE INVENTION
[0010] Within one aspect the invention provides a method of
promoting blood flow within the vasculature of a mammal comprising
administering to said mammal a therapeutically effective amount of
an adipocyte complement related protein; in a pharmaceutically
acceptable vehicle; whereby said adipocyte complement related
protein reduces thrombogenic and complement activity within said
vasculature. Within one embodiment the adipocyte complement related
protein comprises a polypeptide comprising a sequence of amino acid
residues that is at least 75% identical in amino acid sequence to
residues 26-281 of SEQ ID NO: 2, wherein said sequence comprises:
Gly-Xaa-Xaa or Gly-Xaa-Pro repeats forming a collagen domain,
wherein Xaa is any amino acid, and a carboxy-terminal globular
portion. Within a related embodiment the polypeptide comprises a
sequence of amino acid residues that is at least 90% identical in
amino acid sequence to residues 22-281 of SEQ ID NO: 2. Within
another embodiment the polypeptide comprises an amino acid sequence
that is at least 90% identical in amino acid sequence to residues
26-281 of SEQ ID NO: 2. Within yet another embodiment any
differences between said polypeptide and SEQ ID NO: 2 are due to
conservative amino acid substitutions. Within another embodiment
the collagen domain consists of 13 Gly-Xaa-Xaa repeats and 1
Gly-Xaa-Pro repeat. Within yet another embodiment the globular
domain consists of ten beta sheets. Within a related embodiment the
beta sheets are associated with amino acid residues corresponding
to 147-151, 170-172, 178-181, 191-203, 207-214, 219-225, 227-239,
244-250, and 269-274 of SEQ ID NO: 2. Within yet another embodiment
the polypeptide comprises residues 1-281 of SEQ ID NO: 2 or
residues 1-281 of SEQ ID NO: 44.
[0011] The invention also provided the polypeptide is complexed to
a second polypeptide to form a oligomer. Within one embodiment the
polypeptides are complexed by intermolecular disulfide bonds.
Within another embodiment the oligomer is a trimer. Within yet
another embodiment the oligomer is a hexamer. Within yet another
embodiment the oligomer is an 18mer.
[0012] Within another embodiment the polypeptide reduces
thrombogenic and complement activity by inhibition of the
complement pathway and inhibition collagen-mediated platelet
adhesion, activation or aggregation. Within another embodiment
polypeptide is administered prior to, during or following an acute
vascular injury in said mammal. Within yet another embodiment the
injury is due to vascular reconstruction. Within a related
embodiment the vascular reconstruction comprises angioplasty,
coronary artery bypass graft, endarterectomy, microvascular repair
or anastomosis of a vascular graft. Within another related
embodiment the injury is due to trauma, stroke or aneurysm.
[0013] Within another aspect the invention provides a method of
pacifying damaged collagenous tissues within a mammal comprising
administering to said mammal a therapeutically effective amount of
an adipocyte complement related protein; whereby said protein
renders the damaged collagenous tissue inert towards complement
activation, thrombotic activity or immune activation. Within one
embodiment the damaged collagenous tissues are due to injury
associated with ischemia and reperfusion. Within another embodiment
the injury comprises trauma injury ischemia, intestinal
strangulation, or injury associated with pre- and
post-establishment of blood flow. Within yet another embodiment the
polypeptide is administered to a mammal suffering from
cardiopulmonary bypass ischemia and recesitation, myocardial
infarction, or post-trauma vasospasm. Within a related embodiment
the post-trauma vasospasm comprises stroke, percutanious
transluminal angioplasty, endarterectomy, accidental vascular
trauma or surgical-induced vascular trauma.
[0014] Within yet another aspect the invention provides a method of
pacifying the surface of a prostatic biomaterial for use in
association with a mammal comprising administering to said mammal a
therapeutically effective amount of an adipocyte complement related
protein; whereby said polypeptide renders the surface of said
prosthetic biomaterial inert towards complement activation,
thrombotic activity or immune activation. Within one embodiment the
surface of said prostatic biomaterial is coated with collagen or
collagen fragments, gelatin, fibrin or fibronectin.
[0015] Within another aspect of the invention is provided a method
of mediating wound repair within a mammal comprising administering
to said mammal a therapeutically effective amount of an adipocyte
complement related protein; whereby said polypeptide enhances
progression in wound healing.
BRIEF DESCRIPTION OF THE DRAWINGS
[0016] FIG. 1 illustrates a multiple alignment of and zsig37
polypeptide of the present invention and HUMUPST2.sub.--1 (Maeda et
al., Biochem. Biophys. Res. Comm. 221(2): 286-9, 1996) (SEQ ID NO:
51); C1QA_HUMAN (Sellar et al., Biochem. J. 274: 481-90, 1991,
Reid, Biochem. J. 179: 367-71, 1979, and Reid et al., Biochem. J.
203: 559-69, 1982) (SEQ ID NO: 52); HP25_TAMAS (Takamatsu et al.,
Mol. Cell. Biol. 13: 1516-21, 1993 and Kondo & Kondo, J. Biol.
Chem. 267: 473-8, 1992) (SEQ ID NO: 53); HP27_TAMAS (Takamatsu et
al. and Kondo & Kondo referenced above) (SEQ ID NO: 54); and
CERL_RAT (Wada & Ohtani, Brain Res. Mol. Brain Res. 9: 71-7,
1991) (SEQ ID NO: 55).
[0017] FIG. 2 is a matrix showing percent amino acid identity in a
comparison of the six proteins shown in the multiple alignment FIG.
1.
[0018] FIG. 3a shows zsig37-FITC binding to type VI collagen.
[0019] FIG. 3b shows competition of unlabeled zsig37 with FITC
labeled zsig37 bound to type VI collagen.
[0020] FIG. 4 shows binding of complement C1q-FITC to zsig37.
[0021] FIG. 5 shows inhibition of human complement activity by
zsig37.
[0022] FIG. 6 shows the percent aggregation of platelets by
collagen in the presence of zsig37.
[0023] FIG. 7 shows proliferation of SK5 fibroblasts in the
presence of zsig37.
DETAILED DESCRIPTION OF THE INVENTION
[0024] Prior to setting forth the invention in detail, it may be
helpful to the understanding thereof to define the following
terms.
[0025] The term "affinity tag" is used herein to denote a peptide
segment that can be attached to a polypeptide to provide for
purification or detection of the polypeptide or provide sites for
attachment of the polypeptide to a substrate. In principal,
any-peptide or protein for which an antibody or other specific
binding agent is available can be used as an affinity tag. Affinity
tags include a poly-histidine tract, protein A (Nilsson et al.,
EMBO J. 4:1075, 1985; Nilsson et al., Methods Enzymol. 198:3,
1991), glutathione S transferase (Smith and Johnson, Gene 67:31,
1988), substance P, Flag.TM. peptide (Hopp et al., Biotechnology
6:1204-10, 1988; available from Eastman Kodak Co., New Haven,
Conn.), streptavidin binding peptide, or other antigenic epitope or
binding domain. See, in general Ford et al., Protein Expression and
Purification 2: 95-107, 1991. DNAs encoding affinity tags are
available from commercial suppliers (e.g., Pharmacia Biotech,
Piscataway, N.J.).
[0026] The term "complements of a polynucleotide molecule" is a
polynucleotide molecule having a complementary base sequence and
reverse orientation as compared to a reference sequence. For
example, the sequence 5' ATGCACGGG 3' is complementary to 5'
CCCGTGCAT 3'.
[0027] The term "degenerate nucleotide sequence" denotes a sequence
of nucleotides that includes one or more degenerate codons (as
compared to a reference polynucleotide molecule that encodes a
polypeptide). Degenerate codons contain different triplets of
nucleotides, but encode the same amino acid residue (i.e., GAU and
GAC triplets each encode Asp).
[0028] The term "isolated", when applied to a polynucleotide,
denotes that the polynucleotide has been removed from its natural
genetic milieu and is thus free of other extraneous or unwanted
coding sequences, and is in a form suitable for use within
genetically engineered protein production systems. Such isolated
molecules are those that are separated from their natural
environment and include cDNA and genomic clones. Isolated DNA
molecules of the present invention are free of other genes with
which they are ordinarily associated, but may include naturally
occurring 5' and 3' untranslated regions such as promoters and
terminators. The identification of associated regions will be
evident to one of ordinary skill in the art (see for example, Dynan
and Tijan, Nature 316:774-78, 1985).
[0029] An "isolated" polypeptide or protein is a polypeptide or
protein that is found in a condition other than its native
environment, such as apart from blood and animal tissue. In a
preferred form, the isolated polypeptide is substantially free of
other polypeptides, particularly other polypeptides of animal
origin. It is preferred to provide the polypeptides in a highly
purified form, i.e. greater than 95% pure, more preferably greater
than 99% pure. When used in this context, the term "isolated" does
not exclude the presence of the same polypeptide in alternative
physical forms, such as dimers or alternatively glycosylated or
derivatized forms.
[0030] The term "ortholog" denotes a polypeptide or protein
obtained from one species that is the functional counterpart of a
polypeptide or protein from a different species. Sequence
differences among orthologs are the result of speciation.
[0031] The term "polynucleotide" denotes a single- or
double-stranded polymer of deoxyribonucleotide or ribonucleotide
bases read from the 5' to the 3' end. Polynucleotides include RNA
and DNA, and may be isolated from natural sources, synthesized in
vitro, or prepared from a combination of natural and synthetic
molecules. Sizes of polynucleotides are expressed as base pairs
(abbreviated "bp"), nucleotides ("nt"), or kilobases ("kb"). Where
the context allows, the latter two terms may describe
polynucleotides that are single-stranded or double-stranded. When
the term is applied to double-stranded molecules it is used to
denote overall length and will be understood to be equivalent to
the term "base pairs". It will be recognized by those skilled in
the art that the two strands of a double-stranded polynucleotide
may differ slightly in length and that the ends thereof may be
staggered as a result of enzymatic cleavage; thus all nucleotides
within a double-stranded polynucleotide molecule may not be paired.
Such unpaired ends will in general not exceed 20 nt in length.
[0032] A "polypeptide" is a polymer of amino acid residues joined
by peptide bonds, whether produced naturally or synthetically.
Polypeptides of less than about 10 amino acid residues are commonly
referred to as "peptides".
[0033] "Probes and/or primers" as used herein can be RNA or DNA.
DNA can be either cDNA or genomic DNA. Polynucleotide probes and
primers are single or double-stranded DNA or RNA, generally
synthetic oligonucleotides, but may be generated from cloned cDNA
or genomic sequences or its complements. Analytical probes will
generally be at least 20 nucleotides in length, although somewhat
shorter probes (14-17 nucleotides) can be used. PCR primers are at
least 5 nucleotides in length, preferably 15 or more nt, more
preferably 20-30 nt. Short polynucleotides can be used when a small
region of the gene is targeted for analysis. For gross analysis of
genes, a polynucleotide probe may comprise an entire exon or more.
Probes can be labeled to provide a detectable signal, such as with
an enzyme, biotin, a radionuclide, fluorophore, chemiluminescer,
paramagnetic particle and the like, which are commercially
available from many sources, such as Molecular Probes, Inc.,
Eugene, Oreg., and Amersham Corp., Arlington Heights, Ill., using
techniques that are well known in the art.
[0034] Molecular weights and lengths of polymers determined by
imprecise analytical methods (e.g., gel electrophoresis) will be
understood to be approximate values. When such a value is expressed
as "about" X or "approximately" X, the stated value of X will be
understood to be accurate to .+-.10%.
[0035] All references cited herein are incorporated by reference in
their entirety.
[0036] The present invention was based in part upon the discovery
that a novel adipocyte complement related protein homolog inhibits
collagen-mediated platelet activation and the complement pathway
including C1q. This protein was designated zsig37 and is fully
described in the commonly assigned published PCT patent application
WO 99/04000.
[0037] The zsig37 nucleotide sequence (SEQ ID NO: 1) encodes a
polypeptide (SEQ ID NO: 2) having an amino-terminal signal
sequence, an adjacent N-terminal region of non-homology, a
truncated collagen domain composed of Gly-Xaa-Xaa or Gly-Xaa-Pro
repeats and a carboxy-terminal globular portion. The novel
polynucleotide sequence also contains a long 3' untranslated
region. The general polypeptide structure set forth above is shared
by Acrp3O and HUMUPST2.sub.--1, except that the collagen-like
domain of each of those proteins is longer than that of zsig37
polypeptides. Also, the HUMUPST2.sub.--1 DNA sequence is
characterized by a long 3' untranslated region. Moreover, Acrp30
and all of the sequences aligned in FIG. 1, with the exception of
CERL_RAT, share a conserved cysteine residue at position 187 of
zsig37 polypeptide as shown in FIG. 1 and SEQ ID NO: 2. Also, the
zsig37 polypeptides of the present invention include a putative
N-linked glycosylation site at amino acid 93 (Asn) of SEQ ID NO:
2.
[0038] Analysis of the tissue distribution of the mRNA
corresponding to zsig37 showed that expression was highest in heart
and placenta, with relatively less intense signals in kidney,
ovary, adrenal gland and skeletal muscle and lower signals in a
wide variety of other tissues present on the Northern blot.
[0039] A homolog relationship with adipocyte complement related
protein Acrp30 (SEQ ID NO: 3) and adipocyte secreted protein apM1
(HUMUPST2.sub.--1 in FIGS. 1 and 2) (SEQ ID NO: 51) was established
for zsig37. Somewhat more distant homology was also identified to
complement component C1Q A chain (SEQ ID NO: 52), two factors
observed in the active state of hibernating Siberian woodchucks
(HP25_TAMAS (SEQ ID NO: 53) and HP27_TAMAS (SEQ ID NO: 54)) and a
rat brain protein (CERL_RAT) (SEQ ID NO: 55), as shown in FIGS. 1
and 2.
[0040] The nucleotide sequence of zsig37 is described in SEQ ID NO:
1, and its deduced amino acid sequence is described in SEQ ID NO:
2. A degenerate nucleotide sequence encoding the polypeptide of SEQ
ID NO: 2 is provided in SEQ ID NO: 23. As described generally
above, the zsig37 polypeptide includes a signal sequence, ranging
from amino acid 1 (Met) to amino acid residue 21 (Gly). An
alternative signal sequence ranges from amino acid 1 (Met) to amino
acid 25 (Ser). The mature polypeptide therefore ranges from amino
acid 22 (Leu) or 26 (Arg) to amino acid 281 (Pro). Within the
mature polypeptide, an N-terminal region of no known homology is
found, ranging between amino acid residue 22 (Leu) and 98 (Lys). In
addition, a truncated collagen domain is found between amino acid
99 (Gly) and 140 (Arg). In the truncated collagen domain, 1 perfect
Gly-Xaa-Pro and 13 imperfect Gly-Xaa-Xaa repeats are observed. In
contrast, Acrp30 contains 22 perfect or imperfect repeats. The
zsig37 polypeptide also includes a carboxy-terminal globular
domain, ranging from about amino acid 141 (Cys) to 281 (Pro).
Zsig37 polypeptide, HUMUPST2.sub.--1 and Acrp30 appear to be
homologous within the collagen domain and in the globular domain,
but not in the N-terminal portion of the mature polypeptide.
[0041] The globular C1q domain of ACRP30 has been determined to
have a 10 beta strand "jelly roll" topology (Shapiro and Scherer,
Curr. Biol. 8:335-8, 1998) that shows significant structural
homology to the TNF family and the zsig37 sequence as represented
by SEQ ID NO: 2 contains all 10 beta-strands of this structure
(amino acid residues 147-151, 170-172, 178-181, 185-188, 191-203,
207-214, 219-225, 227-238, 244-250, and 269-274 of SEQ ID NO: 2).
These strands have been designated "A", "A", "B", "B", "C", "D",
"E", "F", "G" and "H" respectively.
[0042] Zsig37 has two receptor binding loops, at amino acid
residues 152-180 and 213-226. Amino acid residues 191 (Gly), 193
(Tyr), 238 (Leu) and 272 (Gly) appear to be conserved across the
superfamily including CD40, TNF.alpha., TNF.beta., ACRP30 and
zsig37.
[0043] Another aspect of the present invention includes use of
zsig37 polypeptide fragments as inhibitors of hemostasis and immune
functions. Preferred fragments include the collagen-like domain, of
zsig37 polypeptides, ranging from amino acid 99 (Gly) to amino acid
140 (Arg) of SEQ ID NO: 2, a portion of the zsig37 polypeptide
containing the collagen-like domain or a portion of the
collagen-like domain capable of dimerization or oligomerization.
Other preferred fragments include the globular domain of zsig37
polypeptides, ranging from amino acid 140 (Arg) or 141 (Cys) to 281
(Pro) of SEQ ID NO: 2, a portion of the zsig37 polypeptide
containing the globular-like domain or an active portion of the
globular-like domain. Another zsig37 polypeptide fragment of the
present invention include both the collagen-like domain and the
globular domain ranging from amino acid residue 99 (Gly) to 281
(Pro) of SEQ ID NO: 2. These fragments are particularly useful in
the inhibition of collagen-mediated platelet activation and
inhibition of complement and C1q.
[0044] The present invention also provides use of zsig37 fusion
proteins. For example, fusion proteins of the present invention
encompass (1) a polypeptide selected from the group comprising: (a)
polypeptide molecules comprising a sequence of amino acid residues
as shown in SEQ ID NO: 2 from amino acid residue 1 (Met), 22 (Leu)
or 26 (Arg) to amino acid residue 281 (Pro); (b) polypeptide
molecules ranging from amino acid 99 (Gly) to amino acid 140 (Arg)
of SEQ ID NO: 2, a portion of the zsig37 polypeptide containing the
collagen-like domain or a portion of the collagen-like domain
capable of dimerization or oligomerization; (c) polypeptide
molecules ranging from amino acid 140 (Arg) or 141 (Cys) to 281
(Pro) of SEQ ID NO: 2, a portion of the zsig37 polypeptide
containing the globular-like domain or an active portion of the
globular-like domain; or (d) polypeptide molecules ranging from
amino acid 99 (Gly) to 281 (Pro), a portion of the zsig37
polypeptide including the collagen-like domain and the globular
domain; and (2) another polypeptide. The other polypeptide may be
alternative or additional globular domain, an alternative or
additional collagen-like domain, a signal peptide to facilitate
secretion of the fusion protein or the like.
[0045] Also useful within the methods of the invention are zsig37
agonists and antagonists. Methods of identifying antagonists are
known in the art. For example, antagonists of the zsig37
polypeptide can be identified by providing cells responsive to a
zsig37 polypeptide, culturing a first portion of the cells in the
presence of zsig37 polypeptide, culturing a second portion of the
cells in the presence of the zsig37 polypeptide and a test
compound, and detecting a decrease in a cellular response of the
second portion of the cells as compared to the first portion of the
cells. In addition to those assays disclosed herein, samples can be
tested for inhibition of zsig37 activity within a variety of assays
designed to measure receptor binding or the stimulation/inhibition
of zsig37-dependent cellular responses. For example,
zsig37-responsive cell lines can be transfected with a reporter
gene construct that is responsive to a zsig37-stimulated cellular
pathway. Reporter gene constructs of this type are known in the
art, and will generally comprise a zsig37-DNA response element
operably linked to a gene encoding an assayable protein, such as
luciferase. DNA response elements can include, but are not limited
to, cyclic AMP response elements (CRE), hormone response elements
(HRE), insulin response element (IRE) (Nasrin et al., Proc. Natl.
Acad. Sci. USA 87:5273-7, 1990) and serum response elements (SRE)
(Shaw et al. Cell 56: 563-72, 1989). Cyclic AMP response elements
are reviewed in Roestler et al., J. Biol. Chem. 263 (19):9063-6,
1988 and Habener, Molec. Endocrinol. 4 (8):1087-94, 1990. Hormone
response elements are reviewed in Beato, Cell 56:335-44; 1989.
Candidate compounds, solutions, mixtures or extracts are tested for
the ability to inhibit the activity of zsig37 on the target cells
as evidenced by a decrease in zsig37 stimulation of reporter gene
expression. Assays of this type will detect compounds that directly
block zsig37 binding to cell-surface receptors, as well as
compounds that block processes in the cellular pathway subsequent
to receptor-ligand binding. In the alternative, compounds or other
samples can be tested for direct blocking of zsig37 binding to
receptor using zsig37 tagged with a detectable label (e.g.,
.sup.125I, biotin, horseradish peroxidase, FITC, and the like).
Within assays of this type, the ability of a test sample to inhibit
the binding of labeled zsig37 to the receptor is indicative of
inhibitory activity, which can be confirmed through secondary
assays. Receptors used within binding assays may be cellular
receptors or isolated, immobilized receptors.
[0046] Also useful within the methods of the invention are
antibodies that specifically bind to zsig37 polypeptide epitopes,
peptides or polypeptides. Methods for preparing polyclonal and
monoclonal antibodies are well, known in the art (see, for example,
Sambrook et al., Molecular Cloning: A Laboratory Manual, Second
Edition, Cold Spring Harbor, N.Y., 1989; and Hurrell, J. G. R.,
Ed., Monoclonal Hybridoma Antibodies: Techniques and Applications,
CRC Press, Inc., Boca Raton, Fla., 1982).
[0047] As would be evident to one of ordinary skill in the art,
polyclonal antibodies can be generated from inoculating a variety
of warm-blooded animals such as horses, cows, goats, sheep, dogs,
chickens, rabbits, mice, hamsters, guinea pigs and rats as well as
transgenic animals such as transgenic sheep, cows, goats or pigs.
Antibodies may also be expressed in yeast and fungi in modified
forms as well as in mammalian and insect cells. The zsig37
polypeptide or a fragment thereof serves as an antigen (immunogen)
to inoculate an animal or elicit an immune response. Suitable
antigens would include the zsig37 polypeptide encoded by SEQ ID NO:
2 from amino acid residue 22-281 of SEQ ID NO: 2, from amino acid
residue 26-281 of SEQ ID NO: 2, or a contiguous 9-281 amino acid
residue fragment thereof. The immunogenicity of a zsig37
polypeptide may be increased through the use of an adjuvant, such
as alum (aluminum hydroxide) or Freund's complete or incomplete
adjuvant. Polypeptides useful for immunization also include fusion
polypeptides, such as fusions of zsig37 or a portion thereof with
an immunoglobulin polypeptide or with an affinity tag. The
polypeptide immunogen may be a full-length molecule or a portion
thereof. If the polypeptide portion is "hapten-like", such portion
may be advantageously joined or linked to a macromolecular carrier
(such as keyhole limpet hemocyanin (KLH), bovine serum albumin
(BSA) or tetanus toxoid) for immunization.
[0048] As used herein, the term "antibodies" includes polyclonal
antibodies, affinity-purified polyclonal antibodies, monoclonal
antibodies, and antigen-binding fragments, such as F(ab').sub.2 and
Fab proteolytic fragments. Genetically engineered intact antibodies
or fragments, such as chimeric antibodies, Fv fragments, single
chain antibodies and the like, as well as synthetic antigen-binding
peptides and polypeptides, are also included. Non-human antibodies
may be humanized by grafting only non-human CDRs onto human
framework and constant regions, or by incorporating the entire
non-human variable domains (optionally "cloaking" them with a
human-like surface by replacement of exposed residues, wherein the
result is a "veneered" antibody). In some instances, humanized
antibodies may retain non-human residues within the human variable
region framework domains to enhance proper binding characteristics.
Through humanizing antibodies, biological half-life may be
increased, and the potential for adverse immune reactions upon
administration to humans is reduced. Alternative techniques for
generating or selecting antibodies useful herein include in vitro
exposure of lymphocytes to zsig37 protein or peptide, and selection
of antibody display libraries in phage or similar vectors (for
instance, through use of immobilized or labeled zsig37 protein or
peptide).
[0049] Antibodies are defined to be specifically binding if: 1)
they exhibit a threshold level of binding activity, and/or 2) they
do not significantly cross-react with related polypeptide
molecules. First, antibodies herein specifically bind if they bind
to a zsig37 polypeptide, peptide or epitope with a binding affinity
(K.sub.a) of 10.sup.6 mol.sup.-1 or greater, preferably 10.sup.7
mol.sup.-1 or greater, more preferably 10.sup.8 mol.sup.-1 or
greater, and most preferably 10.sup.9 mol.sup.-1 or greater. The
binding affinity of an antibody can be readily determined by one of
ordinary skill in the art, for example, by Scatchard analysis
(Scatchard, Ann. NY Acad. Sci. 51: 660-672, 1949).
[0050] Second, antibodies specifically bind if they do not
significantly cross-react with related polypeptides. Antibodies do
not significantly cross-react with related polypeptide molecules,
for example, if they detect zsig37 polypeptide but not known
related polypeptides using a standard Western blot analysis
(Ausubel et al., ibid.). Examples of known related polypeptides
include other members of a protein family such as Acrp30 (SEQ ID
NO: 3), the polypeptides shown in alignment FIG. 1 and the like.
They could also include, if desired, orthologs and mutant human
zsig37 polypeptides. Moreover, antibodies may be "screened against"
known related polypeptides to isolate a population that
specifically binds to the inventive polypeptides. For example,
antibodies raised to human zsig37 polypeptides are adsorbed to
related polypeptides adhered to insoluble matrix; antibodies
specific to human zsig37 polypeptides will flow through the matrix
under the proper buffer conditions. Such screening allows isolation
of polyclonal and monoclonal antibodies non-crossreactive to
closely related polypeptides (Antibodies: A Laboratory Manual,
Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988;
Current Protocols in Immunology, Cooligan, et al. (eds.), National
Institutes of Health, John Wiley and Sons, Inc., 1995). Screening
and isolation of specific antibodies is well known in the art (see,
Fundamental Immunology, Paul (eds.), Raven Press, 1993; Getzoff et
al., Adv. in Immunol. 43: 1-98, 1988; Monoclonal Antibodies:
Principles and Practice, Goding, J. W. (eds.), Academic Press Ltd.,
1996; Benjamin et al., Ann. Rev. Immunol. 2: 67-101, 1984).
Representative examples of such assays include: concurrent
immunoelectrophoresis, radioimmunoassay, radioimmuno-precipitation,
enzyme-linked immunosorbent assay (ELISA), dot blot or Western blot
assay, inhibition or competition assay, and sandwich assay.
[0051] The effect of zsig37 polypeptides, fragments, fusions,
agonists or antagonists on hemostasis, in particular platelet
adhesion and activation leading to platelet aggregation can be
determined by using methods and assays provided herein and those
known in the art. Collagen is a potent inducer of platelet
aggregation. This poses risks to patients recovering from vascular
injures. Inhibitors of collagen-induced platelet aggregation would
be useful for such purposes. Zsig37 was found to bind to
fibronectin and type I, II, III, V and VI collagens. In particular,
zsig37 binds to specific domains on collagen VI in a concentration
dependent manner. Zsig37 was also found to inhibit
collagen-mediated platelet activation. Zsig37-induced inhibition
was selective for collagen activation, zsig37 had no effect on
platelets activated by known platelet activators ADP or thrombin.
These results are described in more detail below in the Example
section below. It is anticipated that zsig37 polypeptides,
fragments, fusions, agonists or antagonists will be useful for
blocking the binding of platelets to collagen-coated surfaces and
reducing associated collagen-induced platelet aggregation.
[0052] C1q is a component of the complement pathway and has been
found to stimulate defense mechanisms as well as trigger the
generation of toxic oxygen species that can cause tissue damage
(Tenner, Behring Inst. Mitt. 93:241-53, 1993). C1q binding sites
are found on platelets. C1q, independent of an immune binding
partner, has been found to inhibit platelet aggregation but not
platelet adhesion or shape change. The amino terminal region of C1q
shares homology with collagen (Peerschke and Ghebrehiwet, J.
Immunol. 145:2984-88, 1990). Zsig37 binds to complement C1q in a
concentration dependent manner. Zsig37 was found to be effective in
inhibiting the complement pathway including C1q with both
sensitized and unsensitized sheep erythrocytes.
[0053] Zsig37 polypeptides, fragments, fusion proteins, antibodies,
agonists or antagonists of the present invention can be used in
methods for promoting blood flow within the vasculature of a mammal
by reducing the number of platelets that adhere and are activated
and the size of platelet aggregates. Such methods would comprise
administration of a therapeutically effective amount of zsig37
polypeptides, fragments, fusions, antibodies, agonists or
antagonists to a mammal in need of such treatment, whereby zsig37
reduces thrombogenic and complement activity within the vasculature
of the mammal. As is described below, zsig37 polypeptides inhibit
collagen-mediated platelet activation and inactivate fibronectin
and type I, II, III, V and VI collagens through binding. Zsig37
administration reduces thrombogenic activity at the site of
vascular injury by reducing the modes for platelet adhesion,
activation and aggregation. Zsig37 also inhibits the complement
pathway and C1q as is described below, thus reducing complement
activity within the vasculature. Zsig37 polypeptides, fragments,
fusions, antibodies, agonists or antagonists used in such methods
can be administered prior to, during or following an acute vascular
injury in the mammal.
[0054] In a preferred method, the vascular injury is due to
vascular reconstruction, including but not limited to, angioplasty,
endarterectomy, coronary artery bypass graft, microvascular repair
or anastomosis of a vascular graft. Also contemplated are vascular
injuries due to trauma, stroke or aneurysm. In other preferred
methods the vascular injury is due to plaque rupture, degradation
of the vasculature, complications associated with diabetes and
atherosclerosis. Plaque rupture in the coronary artery induces
heart attack and in the cerebral artery induces stroke. Use of
zsig37 polypeptides, fragments, fusion proteins, antibodies,
agonists or antagonists in such methods would also be useful for
ameliorating whole system diseases of the vasculature associated
with the immune system, such as disseminated intravascular
coagulation (DIC) and SIDs. Additionally the complement inhibiting
activity would be useful for treating non-vasculature immune
diseases such as arteriolosclerosis.
[0055] A correlation has been found between the presence of C1q in
localized ischemic myocardium and the accumulation of leukocytes
following coronary occlusion and reperfusion. Release of cellular
components following tissue damage triggers complement activation
which results in toxic oxygen products that may be the primary
cause of myocardial damage (Rossen et al., Circ. Res. 62.572-84,
1998 and Tenner, ibid.). Blocking the complement pathway was found
to protect ischemic myocardium from reperfusion injury (Buerke et
al., J. Pharm. Exp. Therp. 286:429-38, 1998). The complement
inhibition and C1q binding activity of zsig37 polypeptides would be
useful for such purposes.
[0056] The collagen and C1q binding capabilities of zsig37 would be
useful to pacify damaged collagenous tissues preventing platelet
adhesion, activation or aggregation, and the activation of
inflammatory processes which lead to the release of toxic oxygen
products. By rendering the exposed tissue inert towards such
processes as complement activity, thrombotic activity and immune
activation, zsig37 polypeptides, fragments, fusions, antibodies,
agonists or antagonists would be useful in reducing the injurious
effects of ischemia and reperfusion. In particular, such injuries
would include trauma injury ischemia, intestinal strangulation, and
injury associated with pre- and post-establishment of blood flow.
Zsig37 would be useful in the treatment of cardiopulmonary bypass
ischemia and recesitation, myocardial infarction and post trauma
vasospasm, such as stroke or percutanious transluminal angioplasty
as well as accidental or surgical-induced vascular trauma.
[0057] Zsig37 polypeptides, fragments, fusions, antibodies,
agonists or antagonists would also be useful to pacify prosthetic
biomaterials and surgical equipment to render the surface of the
materials inert towards complement activation, thrombotic activity
or immune activation. Such materials include, but are not limited
to, collagen or collagen fragment-coated biomaterials,
gelatin-coated biomaterials, fibrin-coated biomaterials,
fibronectin-coated biomaterials, heparin-coated biomaterials,
collagen and gel-coated stents, arterial grafts, synthetic heart
valves, artificial organs or any prosthetic application exposed to
blood that will bind zsig37 at greater than 1.times.10.sup.8.
Coating such materials can be done using methods known in the art,
see for example, Rubens, U.S. Pat. No. 5,272,074.
[0058] Complement and C1q play a role in inflammation. The
complement activation is initiated by binding of C1q to
immunoglobulins (Johnston, Pediatr. Infect. Dis. J. 12:933-41,
1993; Ward and Ghetie, Therap. Immunol. 2:77-94, 1995). Inhibitors
of C1q and complement would be useful as anti-inflammatory agents.
Such application can be made to prevent infection. Additionally,
such inhibitors can be administrated to an individual suffering
from inflammation mediated by complement activation and binding of
immune complexes to C1q. Zsig37 polypeptides, fragments, fusion
proteins, antibodies, agonists or antagonists would be useful in
methods of mediating wound repair, enhancing progression in wound
healing by overcoming impaired wound healing. Progression in wound
healing would include, for example, such elements as a reduction in
inflammation, fibroblasts recruitment, wound retraction and
reduction in infection.
[0059] Ability of tumor cells to bind to collagen may contribute to
the metastasis of tumors. Inhibitors of collagen binding are also
useful for mediating the adhesive interactions and metastatic
spread of tumors (Noeske-Jungbult et al., U.S. Pat. No.
5,723,312).
[0060] Zsig37 was found to induce vasodilatation in
norepinepherin-contracted aortic rings using the procedures of
Dainty et al., J. Pharmacol. 100:767, 1990 and Rhee et al.,
Neurotox. 16:179, 1995, as is described below in greater
detail.
[0061] Platelet adhesion, activation and aggregation can be
evaluated using methods described herein or known in the art, such
as the platelet aggregation assay (Chiang et al., Thrombosis Res.
37:605-12, 1985) and platelet adhesion assays (Peerschke and
Ghebrehiwet, J. Immunol. 144:221-25, 1990) Inhibition of C1q and
the complement pathway can be determined using methods disclosed
herein or know in the art, such as described in Suba and Csako, J.
Immunol. 117:304-9, 1976. Assays for platelet adhesion to collagen
and inhibition of collagen-induced platelet aggregation can be
measured using methods described in Keller et al., J. Biol. Chem.
268:5450-6, 1993; Waxman and Connolly, J. Biol. Chem. 268:5445-9,
1993; Noeske-Jungblut et al., J. Biol. Chem. 269:5050-3 or 1994
Deckmyn et al., Blood 85:712-9, 1995.
[0062] Various in vitro and in vivo models are available for
assessing the effects of zsig37 polypeptides, fragments, fusion
proteins, antibodies, agonists and antagonists on ischemia and
reperfusion injury. See for example, Shandelya et al., Circulation
88:2812-26, 1993; Weisman et al., Science 249:146-151, 1991; Buerke
et al., Circulation 91:393-402, 1995; Horstick et al., Circulation
95:701-8, 1997 and Burke et al., J. Phar. Exp. Therp. 286:429-38,
1998. An ex vivo hamster platelet aggregation assay is described by
Deckmyn et al., ibid. Bleeding times in hamsters and baboons can be
measured following injection of zsig37 polypeptides using the model
described by Deckmyn et al., ibid. The formation of thrombus in
response to administration of proteins of the present invention can
be measured using the hamster femoral vein thrombosis model is
provided by Deckmyn et al., ibid. Changes in platelet adhesion
under flow conditions following administration of zsig37 can be
measured using the method described in Harsfalvi et al., Blood
85:705-11, 1995.
[0063] Complement inhibition and wound healing can be Zsig37
polypeptides, fragments, fusion proteins, antibodies, agonists or
antagonists be assayed alone or in combination with other know
inhibitors of collagen-induced platelet activation and aggregation,
such as palldipin, moubatin or calin, for example.
[0064] Zsig37 polypeptides, fragments, fusion proteins, antibodies,
agonists or antagonists can be evaluated using methods described
herein or known in the art, such as healing of dermal layers in
pigs (Lynch et al., Proc. Natl. Acad. Sci. USA 84: 7696-700, 1987)
and full-thickness skin wounds in genetically diabetic mice
(Greenhalgh et al., Am. J. Pathol. 136: 1235-46, 1990), for
example. The polypeptides of the present invention can be assayed
alone or in combination with other known complement inhibitors as
described above.
[0065] In addition, zsig37 polypeptides, fragments, fusions
agonists or antagonists thereof may be therapeutically useful for
anti-microbial applications. For example, complement component C1q
plays a role in host defense against infectious agents, such as
bacteria and viruses. C1q is known to exhibit several specialized
functions. For example, C1q triggers the complement cascade via
interaction with bound antibody or C-reactive protein (CRP). Also,
C1q interacts directly with certain bacteria, RNA viruses,
mycoplasma, uric acid crystals, the lipid A component of bacterial
endotoxin and membranes of certain intracellular organelles. C1q
binding to the C1q receptor is believed to promote phagocytosis.
C1q also appears to enhance the antibody formation aspect of the
host defense system. See, for example, Johnston, Pediatr. Infect.
Dis. J. 12(11): 933-41, 1993. Thus, soluble C1q-like molecules may
be useful as anti-microbial agents, promoting lysis or phagocytosis
of infectious agents.
[0066] The positively charged, extracellular, triple helix,
collagenous domains of C1q and macrophage scavenger receptor were
determined to play a role in ligand binding and were shown to have
a broad binding specificity for polyanions (Acton et al., J. Biol.
Chem. 268:3530-37, 1993). Lysophospholipid growth factor
(lysophosphatidic acid, LPA) and other mitogenic anions localize at
the site of damaged tissues and assist in wound repair. LPA exerts
many biological effects including activation of platelets and
up-regulation of matrix assembly. It is thought that LPA synergizes
with other blood coagulation factors and mediates wound
healing.
[0067] The collagenous domains of proteins such as C1q and
macrophage scavenger receptor are know to bind acidic phospholipids
such as LPA. A 9mer region of the collagen domain of zsig37, amino
acid residues 127-135 of SEQ ID NO: 2, shares sequence homology
with the collagen domain found on C1q and macrophage scavenger
receptor. The interaction of zsig37 polypeptides, fragments,
fusions, agonists or antagonists with mitogenic anions such as LPA
can be determined using assays known in the art, see for example,
Acton et al., ibid. Inhibition of inflammatory processes by
polypeptides and antibodies of the present invention would also be
useful in preventing infection at the wound site.
[0068] For pharmaceutical use, the proteins of the present
invention can be formulated with pharmaceutically acceptable
carriers for parenteral, oral, nasal, rectal, topical, transdermal
administration or the like, according to conventional methods.
Preferably administration is made at or near the site of vascular
injury. In general, pharmaceutical formulations will include a
zsig37 protein in combination with a pharmaceutically acceptable
vehicle, such as saline, buffered saline, 5% dextrose in water or
the like. Formulations may further include one or more excipients,
preservatives, solubilizers, buffering agents, albumin to prevent
protein loss on vial surfaces, etc. Methods of formulation are well
known in the art and are disclosed, for example, in Remington: The
Science and Practice of Pharmacy, Gennaro, ed., Mack Publishing
Co., Easton Pa., 19.sup.th ed., 1995. Therapeutic doses will
generally be determined by the clinician according to accepted
standards, taking into account the nature and severity of the
condition to be treated, patient traits, etc. Determination of dose
is within the level of ordinary skill in the art.
[0069] As used herein a "pharmaceutically effective amount" of a
zsig37 polypeptide, fragment, fusion protein, agonist or antagonist
is an amount sufficient to induce a desired biological result. The
result can be alleviation of the signs, symptoms, or causes of a
disease, or any other desired alteration of a biological system.
For example, an effective amount of a zsig37 polypeptide is that
which provides either subjective relief of symptoms or an
objectively identifiable improvement as noted by the clinician or
other qualified observer. Such an effective amount of a zsig37
polypeptide would provide, for example, inhibition of
collagen-activated platelet activation and the complement pathway,
including C1q, increase localized blood flow within the vasculature
of a patient and/or reduction in injurious effects of ischemia and
reperfusion. Effective amounts of the zsig37 polypeptides can vary
widely depending on the disease or symptom to be treated. The
amount of the polypeptide to be administered and its concentration
in the formulations, depends upon the vehicle selected, route of
administration, the potency of the particular polypeptide, the
clinical condition of the patient, the side effects and the
stability of the compound in the formulation. Thus, the clinician
will employ the appropriate preparation containing the appropriate
concentration in the formulation, as well as the amount of
formulation administered, depending upon clinical experience with
the patient in question or with similar patients. Such amounts will
depend, in part, on the particular condition to be treated, age,
weight, and general health of the patient, and other factors
evident to those skilled in the art. Typically a dose will be in
the range of 0.01-100 mg/kg of subject. In applications such as
balloon catheters-the typical dose range would be 0.05-5 mg/kg of
subject. Doses for specific compounds may be determined from in
vitro or ex vivo studies in combination with studies on
experimental animals. Concentrations of compounds found to be
effective in vitro or ex vivo provide guidance for animal studies,
wherein doses are calculated to provide similar concentrations at
the site of action.
[0070] The invention is further illustrated by the following
non-limiting examples.
EXAMPLE 1
[0071] Extension of EST Sequence
[0072] The novel zsig37 polypeptide-encoding polynucleotides of the
present invention were initially identified by selecting an EST
from an EST database, predicting a protein sequence based
thereupon, and searching known sequence databases for the secreted
protein that is most homologous to predicted protein based on the
EST. ESTs that potentially encode proteins having biologically
interesting homology to known secreted proteins were identified for
further study. A single EST sequence was discovered and predicted
to be homologous to adipocyte specific protein. See, for example,
Scherer et al., J. Biol. Chem. 270(45): 26746-9, 1995. To identify
the corresponding cDNA, a clone considered likely to contain the
entire coding sequence was used for sequencing. Using an Invitrogen
S.N.A.P..TM. Miniprep kit (Invitrogen, Corp., San Diego, Calif.)
according to manufacturer's instructions a 5 ml overnight culture
in LB+50 .mu.g/ml ampicillin was prepared. The template was
sequenced on an ABIPRISM.TM. model 377 DNA sequencer (Perkin-Elmer
Cetus, Norwalk, Conn.) using the ABI PRISM.TM. Dye Terminator Cycle
Sequencing Ready Reaction Kit (Perkin-Elmer Corp.) according to
manufacturer's instructions. Oligonucleotides ZC695 (SEQ ID NO: 5),
ZC694 (SEQ ID NO: 6) to the SP6 and T7 promoters on the
clone-containing vector were used as sequencing primers.
Oligonucleotides ZC13210 (SEQ ID NO: 7), ZC13588 (SEQ ID NO: 8),
ZC13532 (SEQ ID NO: 9), ZC13641 (SEQ ID NO: 10), ZC13586 (SEQ ID
NO: 11), ZC13651 (SEQ ID NO: 12), ZC13622 (SEQ ID NO: 13), ZC13625
(SEQ ID NO: 14), ZC13650 (SEQ ID NO: 15), ZC13589 (SEQ ID NO: 16),
ZC13624 (SEQ ID NO: 17), ZC13531 (SEQ ID NO: 18), ZC13587 (SEQ ID
NO: 19), and ZC13623 (SEQ ID NO: 20) were used to complete the
sequence from the clone. Sequencing reactions were carried out in a
Hybaid OmniGene Temperature Cycling System (National Labnet Co.,
Woodbridge, N.Y.). SEQUENCHER.TM. 3.0 sequence analysis software
(Gene Codes Corporation, Ann Arbor, Mich.) was used for data
analysis. The resulting 2769 bp sequence is disclosed in SEQ ID NO:
1. Comparison of the originally derived EST sequence with the
sequence represented in SEQ ID NO: 1 showed that there was one-base
pair ambiguity (an unknown "N" residue) and no base pair insertions
which resulted in the identification of leucine in resolution of
the ambiguity and zero frame shifts between the deduced amino acid
sequences.
EXAMPLE 2
[0073] Tissue Distribution
[0074] Northerns were performed using Human Multiple Tissue Blots
from Clontech (Palo Alto, Calif.). A 30 base DNA probe (ZC12447;
SEQ ID NO: 4) to the 5' end of the nucleotide sequence of the
mature protein shown in SEQ ID NO: 1 was radioactively labeled with
.sup.32P using T4 polynucleotide kinase and forward reaction buffer
(GIBCO BRL, Gaithersburg, Md.) according to the manufacturer's
specifications. The probe was purified using a NUCTRAP push column
(Stratagene Cloning Systems, La Jolla, Calif.). EXPRESSHYB
(Clontech, Palo Alto, Calif.) solution was used for
prehybridization and as a hybridizing solution for the Northern
blots. Hybridization took place overnight at 50.degree. C., and the
blots were then washed in 2.times.SSC and 0.1% SDS at RT, followed
by a wash in 1.times.SSC and 0.1% SDS at 68.degree. C. (about
5.degree. C. less than the melting point). One transcript size was
observed at approximately 2.8 kb. Signal intensity was highest for
heart and placenta, with relatively less intense signals in kidney,
ovary, adrenal gland and skeletal muscle and lower signals in a
wide variety of other tissues present on the Northern blot.
[0075] Additional Northern Blot Analysis was done using a Gut
Northern Tissue Blot. The blot was prepared using mRNA from human
colorectal adenocarcinoma cell line SW480 (Clontech, Palo Alto,
Calif.), human small intestine tissue (Clontech), human stomach
tissue (Clontech), human intestinal smooth muscle cell line (Hism;
ATCC No.CRL-1692; American Type Culture Collection, 12301 Parklawn
Drive, Rockville, Md.), normal human colon cell line (FHC; ATCC No.
CRL-1831; American Type Culture Collection) and human normal fetal
small intestine cell line (FHs74 Int.; ATCC No. CCL241; American
Type Culture Collection).
[0076] Total RNAs were isolated from Hism, FHC and FHs74 Int. by
acid guanidium method (Cheomczynski et al., Anal. Biochem.
162:156-9, 1987). The polyA.sup.+ RNAs were selected by eluting
total RNA through a column that retains polyA.sup.+ RNAs (Aviv et
al., Proc. Nat. Acad. Sci. 69:1408-12, 1972). 2 .mu.g of
polyA.sup.+ RNA from each sample was separated out in a 1.5%
agarose gel in 2.2 M formaldehyde and phosphate buffer. The RNAs
were transferred onto Nytran membrane (Schleicher and Schuell,
Keene, N.H.) in 20.times.SSC overnight. The blot was treated in the
UV Stratalinker 2400 (Stratagene, La Jolla, Calif.) at 0.12 Joules.
The bolt was then baked at 80.degree. C. for one hour.
[0077] Full length cDNA (shown in SEQ ID NO: 1) was amplified by
PCR and radiolabeled with .sup.32P dCTP using a Rediprime pellet
kit (Amersham, Arlington Heights, Ill.) according to the
manufacturer's specifications. The blot was hybridized in
EXPRESSHYB (Clontech) at 56.degree. C. overnight. The blot was
washed at room temperature in 2.times.SSC and 0.1% SDS, then in
2.times.SSC and 0.1% SDS at 65.degree. C., and finally at
65.degree. C. in 0.1.times.SSC and 0.1% SDS. Results showed that
zsig37 hybridized to all tissues except the human intestinal smooth
muscle cell line HISM.
EXAMPLE 3
[0078] Chromosomal Mapping of the Zsig37 Gene
[0079] The zsig37 gene was mapped to human chromosome 17, region
17q25.2, by PCR using the NIGMS Human/Rodent Somatic Cell Hybrid
Mapping Panel Number 2 (National Institute of General Medical
Sciences, Coriell Institute of Medical Research). The panel
consists of DNA isolated from 24 human/rodent somatic cell hybrids
each retaining one specific human chromosome and the parental DNAs.
For the mapping of the zsig37 gene, 20 .mu.l reactions were set up
in a 96-well microtiter plate (Stratagene, La Jolla, Calif.) and
used in a "RoboCycler Gradient 96" thermal cycler (Stratagene).
Each of the 27 PCR reactions consisted of 2 .mu.l 10.times. KlenTaq
PCR reaction buffer (Clontech Laboratories, Inc., Palo Alto,
Calif.), 1.6 .mu.l dNTPs mix (2.5 mM each, PERKIN-ELMER, Foster
City, Calif.), 1 .mu.l sense primer (SEQ ID NO: 21), 1 .mu.l
antisense primer(SEQ ID NO: 22), 2 .mu.l RediLoad (Research
Genetics, Inc.), 0.4 .mu.l 50.times. Advantage KlenTaq Polymerase
Mix (Clontech Laboratories, Inc.), 25 ng of DNA from an individual
hybrid clone or control and ddH.sub.2O for a total volume of 20
.mu.l. The reactions were overlaid with an equal amount of mineral
oil and sealed. The PCR cycler conditions were as follows: an
initial 1 cycle 5 minute denaturation at 95.degree. C., 35 cycles
of a 1 minute denaturation at 95.degree. C., 1 minute annealing at
60.degree. C. and 1.5 minute extension at 72.degree. C., followed
by a final 1 cycle extension of 7 minutes at 72.degree. C. The
reactions were separated by electrophoresis on a 3% NuSieve GTG
agarose gel (FMC Bioproducts, Rockland, Me.).
EXAMPLE 4
[0080] Creation of Mammalian Expression Vectors zsiq37NEE/pZP9 and
zsiq37CEE/pZP9
[0081] Two expression vectors were prepared for the zsig37
polypeptide, zSIG37NEE/pZP9 and zSIG37CEE/pZP9, wherein the
constructs were designed to express a zsig37 polypeptide having a
C- or N-terminal Glu-Glu tag.
[0082] Zsig37NEE/pZP9
[0083] A 800 bp PCR generated zsig-37 DNA fragment was created
using ZC15040 (SEQ ID NO: 24) and ZC15033 (SEQ ID NO: 25) as PCR
primers and the template described in Example 1 above. The PCR
reaction was incubated at 94.degree. C. for 3 minutes, and then run
for 5 cycles of 94.degree. C. for 30 seconds, 30.degree. C. for 20
seconds and 72.degree. C. for 1 minute, followed by 25 cycles at
94.degree. C. for 30 seconds, 64.degree. C. for 20 seconds and
72.degree. C. for 1 minute. A 5 minute extension at 72.degree. C.
followed. The resultant PCR product was then run on a 0.9% TBE
agarose gel with 1.times. TBE buffer. A band of the predicted size
was excised and the DNA was purified from the gel with a Qiaex
II.RTM. resin (Qiagen) according the manufacturer's instructions.
The DNA was digested with the restriction enzymes Bam HI and Xba I,
followed by extraction and precipitation.
[0084] The excised, restriction digested zsig37 DNA fragment was
subcloned into plasmid NEE/pZP9 which had been cut with the
restriction enzymes Bam HI and Xba I. The zsig37NEE/pZP9 expression
vector incorporates the TPA leader and attaches a Glu-Glu tag (SEQ
ID NO: 26) to the N-terminal of the zsig37 polypeptide-encoding
polynucleotide sequence. Plasmid NEE/pZP9 (deposited at the
American Type Culture Collection, 12301 Parklawn Drive, Rockville,
Md., ATCC No. 98668) is a mammalian expression vector containing,
an expression cassette having the mouse metallothionein-1 promoter,
a TPA leader peptide followed by the sequence encoding the Glu-Glu
tag (SEQ ID NO: 26), multiple restriction sites for insertion of
coding sequences, and a human growth hormone terminator. The
plasmid also contains an E. coli origin of replication, a mammalian
selectable marker expression unit having an SV40 promoter, enhancer
and origin of replication, a DHFR gene and the SV40 terminator.
[0085] zsig376CEE/pZP9
[0086] A 866 bp PCR generated zsig37 DNA fragment was created in
accordance with the procedure set forth above using ZC15721 (SEQ ID
NO: 27) and ZC15035 (SEQ ID NO: 28) as PCR primers. The purified
PCR fragment was digested with the restriction enzymes Eco RI and
Bam HI, gel purified using a Qiaex II resin as described above.
[0087] The excised and restriction digested zsig37 DNA was
subcloned into plasmid CEE/pZP9 which had been cut with Eco RI and
Bam HI. The zsig37CEE/pZP9 expression vector uses the native zsig37
signal peptide, and the Glu-Glu epitope (SEQ ID NO: 26) is attached
at the C-terminus as a purification aid. Plasmid CEE/pZP9
(deposited at the American Type Culture Collection, 12301 Parklawn
Drive, Rockville, Md., ATCC No. 98668) is a mammalian expression,
vector containing an expression cassette having the mouse
metallothionein-1 promoter, multiple restriction sites for
insertion of coding sequences, a sequence encoding the Glu-Glu tag
(SEQ ID NO: 26), a stop codon and a human growth hormone
terminator. The plasmid also has an E. coli origin of replication,
a mammalian selectable marker expression unit having an SV40
promoter, enhancer and origin of replication, a DHFR gene and the
SV40 terminator.
[0088] For the N- and C-tagged constructs, about 30 ng of the
restriction digested inserts and 50 ng of the corresponding vectors
were ligated at room temperature for 4 hours. One microliter of
each ligation reaction was independently electroporated into DH10B
competent cells (GIBCO BRL, Gaithersburg, Md.) according to
manufacturer's direction and plated onto LB plates containing 50
mg/ml ampicillin, and incubated overnight.
[0089] Colonies were screened by PCR as described above. For
zsig37NEE/pZP9 and zsig37CEE/pZP9 screens the primers were ZC13006
(SEQ ID NO: 29) and ZC13007 (SEQ ID NO: 20). The PCR reaction was
incubated at 94.degree. C. for 2.5 minutes, and then run for 25
cycles of 94.degree. C. for 10 seconds, 58.degree. C. for 20
seconds and 72.degree. C. for 1 minute. A 5 minute extension at
72.degree. C. followed. The insert sequence of positive clones,
1013 bp for zsig37NEE and a 950 bp fragment for zsig37CEE were
verified by sequence analysis. A large scale plasmid preparation
was done using a QIAGEN.RTM. Maxi prep kit (Qiagen) according to
manufacturer's instructions.
EXAMPLE 5
[0090] Transfection and Expression of zsiq37NEE and CEE
Polypeptides
[0091] BHK 570 cells (ATCC No. CRL-10314) were plated in 10 cm
tissue culture dishes and allowed to grow to approximately 50 to
70% confluency overnight at 37.degree. C., 5% CO.sub.2, in DMEM/FBS
media (DMEM, Gibco/BRL High Glucose, (Gibco BRL, Gaithersburg,
Md.), 5% fetal bovine serum (Hyclone, Logan, Utah), 2 .mu.M
L-glutamine (JRH Biosciences, Lenexa, Kans.), 1 .mu.M sodium
pyruvate (Gibco BRL)). The cells were then transfected with the
plasmid zsig37NEE/pZP9 (N-terminal Glu-Glu tag) or zsig37CEE/pZP9
(C-terminal Glu-Glu tag), using Lipofectamine.TM. (Gibco BRL), in
serum free (SF) media formulation (DMEM, Gibco/BRL High Glucose,
(Gibco BRL, Gaithersburg, Md.), 2 mM L-glutamine, 2 mM sodium
pyruvate, 10 ug/ml transferrin, 5 .mu.g/ml insulin, 10 .mu.g/ml
fetuin and 2 ng/ml selenium). Sixteen micrograms of zsig37NEE/pZP9
and 16 .mu.g of zsig37CEE/pZP9 were separately diluted into 15 ml
tubes to a total final volume of 640 .mu.l SF media. In separate
tubes, 35 .mu.l of Lipofectamine.TM. (Gibco BRL) was mixed with 605
.mu.l of SF medium. The Lipofectamine.TM. mix was added to the DNA
mix and allowed to incubate approximately 30 minutes at room
temperature. Five milliliters of SF media was added to the
DNA:Lipofectamine.TM. mixture. The cells were rinsed once with 5 ml
of SF media, aspirated, and the DNA:Lipofectamine.TM. mixture was
added. The cells were incubated at 37.degree. C. for five hours,
then 6.4 ml of DMEM/10% FBS, 1% PSN media was added to the plate.
The plate was incubated at 37.degree. C. overnight and the
DNA:Lipofectamine.TM. mixture was replaced with fresh FBS/DMEM
media the next day. On day 2 post-transfection, the cells were
split into the selection media (ESTEP #1 with 1 .mu.M MTX) in 150
mm plates at 1:50, 1:100 and 1:200. The plates were refed at day 5
post-transfection with fresh selection media.
[0092] Screening Colonies
[0093] Approximately 10-12 days post-transfection, one 150 mm
culture dish of methotrexate resistant colonies was chosen from
each transfection, the media aspirated, the plates washed with 10
ml serum-free ESTEP 2 media (668.7 g/50L DMEM (Gibco), 5.5 g/50L
pyruvic acid, sodium salt 96% (Mallinckrodt), 185.0 g/50L
NaHCO.sub.3 (Mallinkrodt), 5.0 mg/ml, 25 ml/50L insulin, 10.0 mg/ml
and 25 ml/50 L transferrin). The wash media was aspirated and
replaced with 5 ml serum-free ESTEP 2. Sterile Teflon mesh
(Spectrum Medical Industries, Los Angeles, Calif.) pre-soaked in
serum-free ESTEP 2 was then placed over the cells. A sterile
nitrocellulose filter pre-soaked in serum-free ESTEP 2 was then
placed over the mesh. Orientation marks on the nitrocellulose were
transferred to the culture dish. The plates were then incubated for
5-6 hours in a 37.degree. C., 5% CO.sub.2 incubator. Following
incubation, the filter was removed, and the media aspirated and
replaced with DMEM/5% FBS, 1.times.PSN (Gibco BRL) media. The
filter was then placed into a sealable bag containing 50 ml buffer
(25 mM Tris, 25 mM glycine, 5 mM .beta.-mercaptoethanol) and
incubated in a 65.degree. C. water bath for 10 minutes. The filters
were blocked in 10% nonfat dry milk/Western A buffer (Western A: 50
mM Tris pH 7.4, 5 mM EDTA, 0.05% NP-40, 150 mM NaCl and 0.25%
gelatin) for 15 minutes at room temperature on a rotating shaker.
The filter was then incubated with an anti-Glu-Glu antibody-HRP
conjugate at a 1:1000 dilution in 2.5% nonfat dry milk/Western A
buffer (Western A: 50mM Tris pH 7.4, 5 mM EDTA, 0.05% NP-40, 150 mM
NaCl and 0.25% gelatin) overnight at 4.degree. C. on a rotating
shaker. The filter was then washed three times at room temperature
in PBS plus 0.1% Tween 20, 5-15 minutes per wash. The filter was
developed with ECL reagent (Amersham Corp., Arlington Heights,
Ill.) according the manufacturer's directions and exposed to film
(Hyperfilm ECL, Amersham) for approximately 5 minutes.
[0094] The film was aligned with the plate containing the colonies.
Using the film as a guide, suitable colonies were selected.
Sterile, 3 mm coloning discs (PGC Scientific Corp., Frederick, Md.)
were soaked in trypsin, and placed on the colonies. Twelve colonies
for each construct were transferred into 200 .mu.l of selection
medium in a 96 well plate. A series of seven, two-fold dilutions
were carried out for each colony. The cells were grown for one week
at 37.degree. C. at which time the wells which received the lowest
dilution of cells which are now at the optimum density were
selected, trypsinized and transferred to a 12 well plate containing
selection media. The 150 mm culture dish was also trypsinized and
the remainder of the cells were pooled and subjected to western
analysis and mycoplasma testing. The pool was frozen for
storage.
[0095] The clones were expanded directly from the 12 well plate
into two T-75 flasks. One flask was kept to continue cell growth,
the second flask was grown in serum-free ESTEP 2 which was
harvested for Western Blot analysis. Clones of each of the
expression constructs, based on Western blot analysis, were
selected, pooled and transferred to large scale culture.
EXAMPLE 7
[0096] Large Scale Mammalian Expression of zsiq37CEE
[0097] One T-162 flask, containing confluent cells expressing
zsig37CEE and one containing zsig37NEE obtained from the expression
procedure described above, were expanded into four T-162 flasks
each. One of the four resulting flasks was used to freeze down four
cryovials, and the other three flasks were used to generate a Nunc
cell factory.
[0098] The cells from the three T-162 flasks of zsig37CEE and
zsig37NEE were used to independently seed two Nunc cell factories
(10 layers, commercially available from VWR). Briefly, the cells
from the T-162 flasks described above were detached using trypsin,
pooled, and added to 1.5 liters ESTEP1 media (668.7 g/50L DMEM
(Gibco), 5.5 g/50L pyruvic acid, sodium salt 96% (Mallinckrodt),
185.0 g/50L NaHCO.sub.3 (Mallinkrodt), 5.0 mg/ml and 25 ml/50L
insulin (JRH Biosciences), 10.0 mg/ml and 25 ml/50L transferrin
(JRH Biosciences), 2.5L/50L fetal bovine serum (characterized)
(Hyclone), 1 .mu.M MTX, with pH adjusted to 7.05+/-0.05) prewarmed
to 37.degree. C. The media containing the cells was then poured
into the Nunc cell factories via a funnel. The cell factories were
placed in a 37.degree. C./5.0% CO.sub.2 incubator.
[0099] At 80-100% confluence, a visual contamination test (phenol
red color change) was performed on the contents of the Nunc cell
factories. Since no contamination was observed, supernatant from
the confluent factories was poured into a small harvest container,
sampled and discarded. The adherent cells were then washed once
with 400 ml PBS. To detach the cells from the factories, 100 mls of
trypsin was added to each and removed and the cells were then
incubated for 5 to 10 minutes in the residual trypsin. The cells
were collected following two, 200 ml washes with ESTEP1 media. To
each of ten ESTEP1 media-containing bottles (1.5 liters each, at
37.degree. C.) was added 40 mls of collected cells. One 1.5 liter
bottle was then used to fill one Nunc factory. Each cell factory
was placed in a 37.degree. C./5.0% CO.sub.2 incubator.
[0100] At 80-90% confluence, a visual contamination test (phenol
red color change) was performed on the Nunc cell factories. Since
no contamination was observed, supernatant from the confluent
factories was poured into a small harvest container, sampled and
discarded. Cells were then washed once with 400 ml PBS. 1.5 liters
of ESTEP2 media (668.7 g/50L DMEM (Gibco), 5.5 g/50L pyruvic acid,
sodium salt 96% (Mallinckrodt), 185.0 g/50L NaHCO.sub.3
(Mallinkrodt), 5.0 mg/ml, 25 ml/50L insulin, 10.0 mg/ml and 25
ml/50L transferrin) was added to each Nunc cell factory. The cell
factories were incubated at 37.degree. C./5.0% CO.sub.2.
[0101] At approximately 48 hours a visual contamination test
(phenol red color change) was performed on the Nunc cell factories.
Supernatant from each factory was poured into small harvest
containers. Fresh serum-free media (1.5 liters) was poured into
each Nunc cell factory, and the factories were incubated at
37.degree. C./5.06 CO.sub.2. One ml of supernatant harvest for each
construct was transferred to a microscope slide, and subjected to
microscopic analysis for contamination. The contents of the small
harvest containers for each construct were pooled and immediately
filtered. A second harvest was then performed, substantially as
described above at 48 hours and the cell factories were discarded
thereafter. An aseptically assembled filter train apparatus was
used for aseptic filtration of the harvest supernatant (conditioned
media). Assembly was as follows: tubing was wire-tied to an
Opti-Cap filter (Millipore Corp., Bedford, Mass.) and a Gelman
Supercap 50 filter (Gelman Sciences, Ann Arbor, Mich.). The
Supercap 50 filter was also attached to a sterile capped container
located in a hood; tubing located upstream of the Millipore
Opti-cap filter was inserted into a peristaltic pump; and the free
end of the tubing was placed in the large harvest container. The
peristaltic pump was run between 200 and 300 rpm, until all of the
conditioned media passed through the 0.22 .mu.m final filter into a
sterile collection container. The filtrate was placed in a
4.degree. C. cold room pending purification. The media was
concentrated 10.times. with a Millipore 5 kDA cut off concentrator
(Millipore Corp., Bedford, Mass.) according to manufacturer's
direction and subjected to Western Blot analysis using an anti-FLAG
tag antibody (Kodak).
[0102] Zsiq37CEE:
[0103] 5 T-162 Flasks=0.12 mg/L, 38 kDa;
[0104] 1 Factory, FBS=0.12 mg/L, 38 kDa;
[0105] 10 Factories, FBS=0.12 mg/L, 38 kDa;
[0106] 10 Factories (#1), SF=1.2 mg/L, 38 kDa; and
[0107] 10 Factories (#2), SF=3.56 mg/L, 38 kDa
[0108] Zsiq37NEE:
[0109] 5 T-162 Flasks=0.137 mg/L, 35 kDa;
[0110] 1 Factory, FBS=0.137 mg/L, 35 kDa;
[0111] 10 Factories, FBS=0.137 mg/L, 35 kDa;
[0112] 10 Factories (#1), SF=1.37 mg/L, 35 kDa; and
[0113] 10 Factories (#2), SF=4.11 mg/L, 35 kDa.
EXAMPLE 7
[0114] Purification of zsiq37 NEE and zsiq37 CEE
[0115] Unless otherwise noted, all operations were carried out at
4.degree. C. The following procedure was used for purifying zsig37
containing N-terminal or C-terminal Glu-Glu (EE) tags. A total of
25 liters of conditioned media from baby hamster kidney (BHK) cells
was sequentially sterile filtered through a 4 inch, 0.2 mM
Millipore (Bedford, Mass.) OptiCap capsule filter and a 0.2 mM
Gelman (Ann Arbor, Mich.) Supercap 50. The material was then
concentrated to about 1.3 liters using a Millipore ProFlux A30
tangential flow concentrator fitted with a 3000 kDa cutoff Amicon
(Bedford, Mass.) S10Y3 membrane. The concentrated material was
again sterile-filtered with the Gelman filter as described above. A
mixture of protease inhibitors was added to the concentrated
conditioned media to final concentrations of 2.5 mM
ethylenediaminetetraacetic acid (EDTA, Sigma Chemical Co. St.
Louis, Mo.), 0.001 mM leupeptin (Boehringer-Mannheim, Indianapolis,
Ind.), 0.001 mM pepstatin (Boehringer-Mannheim) and 0.4 mM Pefabloc
(Boehringer-Mannheim). A 25.0 ml sample of anti-EE Sepharose,
prepared as described below, was added to the sample for batch
adsorption and the mixture was gently agitated on a Wheaton
(Millville, N.J.) roller culture apparatus for 18.0 h at 4.degree.
C.
[0116] The mixture was then poured into a 5.0.times.20.0 cm
Econo-Column (Bio-Rad, Laboratories, Hercules, Calif.) and the gel
was washed with 30 column volumes of phosphate buffered saline
(PBS). The unretained flow-through fraction was discarded. Once the
absorbance of the effluent at 280 nM was less than 0.05, flow
through the column was reduced to zero and the anti-EE Sepharose
gel was washed batch-wise with 2.0 column volumes of PBS containing
0.4 mg/ml of EE peptide (AnaSpec, San Jose, Calif.). The peptide
used has the sequence Glu-Tyr-Met-Pro-Val-Asp, SEQ ID NO: 31).
After 1.0 h at 4.degree. C., flow was resumed and the eluted
protein was collected. This fraction was referred to as the peptide
elution. The anti-EE Sepharose gel was then washed with 2.0 column
volumes of 0.1 M glycine, pH 2.5, and the glycine wash was
collected separately. The pH of the glycine-eluted fraction was
adjusted to 7.0 by the addition of a small volume of 10.times.PBS
and stored at 4.degree. C. for future analysis if needed.
[0117] The peptide elution was concentrated to 5.0 ml using a
15,000 molecular weight cutoff membrane concentrator (Millipore,
Bedford, Mass.) according to the manufacturer's instructions. The
concentrated peptide elution was separated from free peptide by
chromatography on a 1.5.times.50 cm Sephadex G-50 (Pharmacia,
Piscataway, N.J.) column equilibrated in PBS at a flow rate of 1.0
ml/min using a BioCad Sprint HPLC (PerSeptive BioSystems,
Framingham, Mass.). Two-ml fractions were collected and the
absorbance at 280 nM was monitored. The first peak of material
absorbing at 280 nM and eluting near the void volume of the column
was collected. This fraction was pure zsig37 NEE or zsig37 CEE. The
pure material was concentrated as described above, analyzed by
SDS-PAGE and Western blotting with anti-EE antibodies, and samples
were taken for amino acid analysis and N-terminal sequencing. The
remainder of the sample was aliquoted, and stored at -80.degree. C.
according to our standard procedures.
[0118] Electrophoresis of zsig37 NEE on SDS-PAGE gels in the
absence of reducing agents, showed one major Coomassie Blue-stained
band of apparent molecular weight 39,000 and several minor
components of molecular weights between 60,000 and 116,000. All of
the bands showed cross reactivity with anti-EE antibodies on
Western blots. In the presence of reducing agent, the only band
observed was the 39,000 kDa protein, and its Coomassie Blue
staining intensity was increased. This band also showed
cross-reactivity with the anti-EE antibody on Western blots.
[0119] For zsig37 CEE, electrophoresis on SDS-PAGE gels in the
absence of reducing agents showed one major Coomassie Blue-stained
band of apparent molecular weight 39,000 and several minor
components of molecular weights between 60,000 and 116,000. On
Western blots, only bands of apparent molecular weights 150,000,
116,000, and 60,000 showed cross-reactivity with the anti-EE
antibody. In the presence of reducing agents, only the Coomassie
Blue-stained band at 39,000 kDa was observed and this material
showed cross-reactivity with the anti-EE antibody on Western blots.
Under these conditions, a small amount of cross-reactive material
was also seen at 150,000 kDa.
[0120] Preparation of Anti-EE Sepharose
[0121] A 100 ml bed volume of protein G-Sepharose (Pharmacia,
Piscataway, N.J.) was washed 3 times with 100 ml of PBS containing
0.02% sodium azide using a 500 ml Nalgene 0.45 micron filter unit.
The gel was washed with 6.0 volumes of 200 mM triethanolamine, pH
8.2 (TEA, Sigma, St. Louis, Mo.) and an equal volume of EE antibody
solution containing 900 mg of antibody was added. After an
overnight incubation at 4.degree. C., unbound antibody was removed
by washing the resin with 5 volumes of 200 mM TEA as described
above. The resin was resuspended in 2 volumes of TEA, transferred
to a suitable container, and dimethylpimilimidate-2HCl (Pierce,
Rockford, Ill.), dissolved in TEA, was added to a final
concentration of 36 mg/ml of gel. The gel was rocked at room
temperature for 45 min and the liquid was removed using the filter
unit as described above. Nonspecific sites on the gel were then
blocked by incubating for 10 min at room temperature with 5 volumes
of 20 mM ethanolamine in 200 mM TEA. The gel was washed with 5
volumes of PBS containing 0.02% sodium azide and stored in this
solution at 4.degree. C.
EXAMPLE 8
[0122] Adhesion and Proliferation Assays
[0123] The ability of zsig37 to stimulate adhesion and spreading of
TF-1 cells was assayed as follows. A series of dilutions were
prepared from C-terminal Glu-Glu-tagged zsig37, from 10 to 0.0625
.mu.g/ml, in either PBS or ELISA coating buffer (0.1 M NaCO.sub.3)
and each was plated into a 96 well plate (Costar, Pleasanton,
Calif.) at 100 .mu.l/well. The plates were incubated at 37.degree.
C., 5% CO.sub.2 for 2 hours. The plates were then washed 3.times.
with RPMI/10% FBS (RPMI 1640, 2 mM L-glutamine, 110 .mu.g/ml sodium
pyruvate, PSN and 10% heat inactivated fetal bovine serum) and
allowed to block for 15 minutes.
[0124] TF-1 cells (derived from acute myeloid leukemia cells) were
resuspended in RPMI/10% FBS and plated into at 10,000 cells/well
into the zsig37CEE,-coated 96 well plates at a final volume of 120
.mu.l/well. The plate was incubated at 37.degree. C. under 5%
CO.sub.2 for 2 hours. The plates were then washed 3.times. with PBS
and 200 .mu.l/well growth media (RPMI/10% FBS, 5 ng/ml GM-CSF) was
added. The cells were microscopically inspected before and after
the wash.
[0125] A dye incorporation assay was also used to quantitatively
measure the number of adherent cells based on a colorimetric change
and an increase in fluorescent signal. Alamar Blue.TM. (AccuMed,
Chicago, Ill.) was added to the 96 well plates and the cells were
incubated at 37.degree. C. under 5% CO.sub.2 overnight. The plates
were then scanned using a fluorometer with excitation wavelength of
544 nm and emission wavelength of 590 nm. There were more adherent
cells on the zsig37CEE-PBS coated plates than on the zsig37CEE-0.1
M NaCO.sub.3 coated plates. Addition of soluble zsig37 did not
block adhesion of cells to the bound zsig37.
[0126] A second assay was done using TF-1, DA-1 (an IL-3 dependent
cell line derived from the lymph node of a mouse with a B-cell
lymphoma by outgrowth in IL-3 media (provided by Dr. Kenneth
Kaushansky, University of Washington, Seattle, Wash.)), pre-B
(p53-/- mouse marrow cells, IL-7 dependent, B220+, Thy1 low,
Sca-1+), and A7BaF-3 cell lines as described above at 5,000
cells/well. BHK cells were also plated at 500 cells/well. Zsig37
enhanced the growth of A7-BaF-3 cells and slightly inhibited growth
of DA-1 cells.
EXAMPLE 9
[0127] Mouse Ortholog Sequence
[0128] The novel human zsig37 polypeptide-encoding polynucleotides
of the present invention were used to screen a mouse EST database
for homologous mouse sequences. A single EST sequence was
discovered and predicted to the human zsig37 sequence. To identify
the corresponding cDNA, a clone considered likely to contain the
entire coding sequence was used for sequencing. Using an Invitrogen
S.N.A.P..TM. Miniprep kit (Invitrogen Corp.) according to
manufacturer's instructions a 5 ml overnight culture in LB+50
.mu.g/ml ampicillin was prepared. The template was sequenced on an
ABIPRISM.TM. model 377 DNA sequencer (Perkin-Elmer Cetus, Norwalk,
Conn.) using the ABI PRISM.TM. Big Dye Terminator Cycle Sequencing
Ready Reaction Kit (Perkin-Elmer Corp.) according to manufacturer's
instructions. Oligonucleotides ZC694 (SEQ ID NO: 6), ZC6768 (SEQ ID
NO: 32), ZC18297 (SEQ ID NO: 33), ZC18298 (SEQ ID NO: 34), ZC18402
(SEQ ID NO: 35), ZC18403 (SEQ ID NO: 36), ZC18456 (SEQ ID NO: 37),
ZC18457 (SEQ ID NO: 38), ZC18560 (SEQ ID NO: 39), ZC18561 (SEQ ID
NO: 40), ZC18687 (SEQ ID NO: 41) and ZC18688 (SEQ ID NO: 42) were
used to complete the sequence from the clone. Sequencing reactions
were carried out in a Hybaid OmniGene Temperature Cycling System
(National Labnet Co., Woodbridge, N.Y.). SEQUENCHER.TM. 3.1
sequence analysis software (Gene Codes Corporation, Ann Arbor,
Mich.) was used for data analysis. The resulting 2559 bp sequence
is disclosed in SEQ ID NO: 43 and the deduced amino acid sequence
in SEQ ID NO: 44. Alignment with the human zsig37 nucleotide
sequence (SEQ ID NO: 1) shows 77% identity at the nucleotide level.
The putative amino acid sequence (SEQ ID NO: 44) has 77% identity
with the human polypeptide sequence (SEQ ID NO: 2).
EXAMPLE 10
[0129] Cell Based Assays
[0130] Zsig37 polypeptides were assayed in a high throughput, in
vitro assay to identify substances that selectively activate
cellular responses in immortalized osteoblast cell lines. A mature
osteoblast cell line derived from p53-/- (deficient) mice, CCC4,
that is transfected with a plasmid containing an inducible serum
response element (SRE) driving the expression of luciferase was
used in the assay. These cells also express endogenous PTH, PDGF
and bFGF receptors. The stimulation of the SRE and thus the
expression of luciferase in the CCC4 cells indicates that the
chemical entity is likely to stimulate mitogenesis in
osteoblasts.
[0131] CCC4 lines were trypsinized and adjusted to 5.times.10.sup.4
cells/ml in plating medium (alpha-MEM, 1% heat inactivated fetal
bovine serum, 1 mM Na pyruvate and 2 mM L-glutamate) and plated
(200 ul/well) into Dynatech Microlite opaque white microtiter
plates (Dynatech, Chantilly, Va.) and incubated overnight at
37.degree. C. 5% CO.sub.2. The growth medium was then aspirated and
replaced with 50 ul/well assay medium (F-12 HAM, 0.5% bovine serum
albumin, 20 mM HEPES, 1 mM Na pyruvate and 2 mM L-glutamate).
Serial dilutions of zsig37 were made in assay medium (0.29-1000
ng/ml final assay concentration) and added to the wells. Zsig37
samples were assayed in triplicate. Serum (negative) and bFGF
(positive) controls were also used. Final concentration of bFGF was
3 ng/ml. Controls were assayed in quadruplicates. The plates were
incubated for 4 hours at 37.degree. C., 5% CO.sub.2. The assay
medium was then aspirated and the plates were rinsed once with PBS.
To each well was then added 25 .mu.l of lysis buffer (Luciferase
Assay Reagent, E1501, Promega Corp., Madison, Wis.). The plates
were incubated for 15 minutes at room temperature. Fifty
microliters/well of luciferase substrate (Luciferase Assay Reagent,
E1501, Promega Corp.) was added and the Luciferase activity was
detected using a Labsystems LUMINOSKAN.RTM. at 2 second/well
following a 1 second delay. The average basal (uninduced) signal
was subtracted from all readings which are expressed in Table 5 as
a percentage of the maximal induction produced by 3 ng/ml bFGF.
[0132] Zsig37 stimulates the expression of luciferase in this assay
indicating that they stimulate osteoblasts. Zsig37 stimulates at 73
to 75% maximal at 1000 ng/ml.
[0133] A counter part growth factor mimetic assay was performed to
determine if zsig37 is acting as a growth factor mimetic,
particularly tyrosine kinase receptor ligands PDGF, bFGF and EGF
(Insulin-R negative). A clonal cell line derived from Swiss 3T3
mice, Swiss 3T3, that is transfected with a plasmid containing an
inducible serum response element (SRE) driving the expression of
luciferase was used in the assay. These cells also express
endogenous PMA, EGF and bFGF receptors. The stimulation of the SRE
and thus the expression of luciferase in the Swiss 3T3 cells
indicates that the chemical entity is likely mimics the PDGF, bFGF
and EGF growth factor activity.
[0134] Swiss 3T3 cells were trypsinized and adjusted to
5.times.10.sup.4 cells/ml in plating medium, plated and incubated
as described above. The growth medium was then aspirated and
replaced with 50 ul/well assay medium (F-12 HAM, 0.5% bovine serum
albumin, 20 mM HEPES). Serial dilutions of zsig37 were made in
assay medium (0.29-1000 ng/ml final assay concentration) and added
to the wells. Zsig37 samples were assayed in triplicate. A serum
(negative) and bFGF (positive) control to promote cell
proliferation were also used. Final concentration of bFGF was 3
ng/ml. Controls were assayed in quadruplicates. The plates were
incubated for 5 hours at 37.degree. C., 5% CO.sub.2. The assay
medium was then aspirated and the plates were rinsed once with PBS.
To each well was then added 25 .mu.l of lysis buffer (Luciferase
Assay Reagent, E1501, Promega Corp., Madison, Wis.). The plates
were incubated for 15 minutes at room temperature. Forty
microliters/well of luciferase substrate (Luciferase Assay Reagent,
E1501, Promega Corp.) was added and the Luciferase activity was
detected using a Labsystems LUMINOSKAN.RTM. at 2 second/well
following a 1 second delay. The average basal (uninduced) signal
was subtracted from all readings which are expressed as a
percentage of the maximal induction produced by 3 ng/ml bFGF. A
five hour treatment of this cell line with bFGF, DDGF, EGF or PMA
leads to a 25-50 fold induction of SRE-luciferase expression.
[0135] Zsig37 does not appear to stimulate the expression of
luciferase in this assay. Zsig37 stimulates at 0.2 to 0.1% maximal
at 1000 ng/ml.
EXAMPLE 10
[0136] In Vivo Administration of zsiq37 Via Adenoviral Delivery
[0137] Twenty four male and 24 female C57B16/J mice, approximately
12 weeks old (Jackson Labs, Bar Harbor, Me.) were weighed, body
temperature was measured and food intake monitored daily for four
days prior to injection (days -4 to -1). On day 0, the mice were
divided into three groups and received 0.1 ml virus (AdV-empty
1.8.times.1011 virus particles/0.1 ml or AdV-zsig37-CEE
5.times.1011 virus particles/0.1 ml) by intravenous tail vein
injection, or no injection at all. Injection should result in
infection of the host's liver and expression of virally delivered
gene should commence within 24 hours and continue for 1 to 4 weeks.
Three groups of mice were tested. Group 1, untreated, n=8 each male
and female. Group 2, AdV-Empty (empty virus), n=8 each male and
female. Group 3, AdV-zsig-37 CEE, n=8 each male and female.
[0138] The animals' body temperatures, weights and the weight of
food ingested was monitored during the three week study. No
difference was found between the groups.
[0139] On day 21 the female mice were euthanized and sacrificed by
cervical dislocation, and on day 22 the males were. The animals
were exsanguinated and tissues harvested for necropsy.
[0140] The standard serum chemistry panel was done at the time of
sacrifice. Liver, kidney and metabolic parameters were all within
normal ranges. There was, however a difference between the zsig37
treatment group and the empty virus treated group. The zsig37
animals had a higher average lipemic index than the empty virus
controls. The difference was not significant, however further
investigation was warranted. Total free fatty acids were assayed on
the remaining serum from each animal. A statistically significant
difference in serum Free Fatty Acid levels was seen between male
mice (p=0.0379) receiving empty virus and those receiving zsig37
encoding virus; the zsig37 mice had higher levels. A difference,
though not statistically significant, was also seen in females
(p=0.3357) Liver, spleen, kidney, thymus, heart and brain were
weighed after removal. No difference was found between the
treatment groups. Histopathological analysis of these tissues and
bone marrow revealed no difference between the treatment
groups.
[0141] To confirm the above results a second screen was done as
above with the following modifications. Three groups; a) untreated
and fasted, b) AdV-null and fasted, c) AdV-zsig37-CEE and fasted,
containing 20 C57B16/J, 10 each male and female, were tested. The
mice were fasted overnight and 100 .mu.l serum was collected to
establish a basal level for the following parameters: fasting
glucose, TP, alkaline phosphatase, cholesterol, triglycerides, free
fatty acids and insulin. Body weights were taken three times a
week. On day 0, mice were injected into the lateral tail vein with
0.1 ml of the appropriate virus solution. Blood was collected on
day 17 following an overnight fast. After 3 weeks the mice were
sacrificed and all blood collected. A portion of the blood was
mixed with EDTA to look at CBC's and the remainder will be
re-assayed and screened as described above. Organs were collected
and the carcass saved for histopathology.
EXAMPLE 11
[0142] Vasodilatation of Aortic Rings
[0143] The effect of zsig37 on vasodilatation of aortic rings was
measured according to the procedures of (Dainty et al., J.
Pharmacol. 100:767, 1990 and Rhee et al., Neurotox. 16: 179, 1995).
Briefly, aortic rings 4 mm in length were taken from 4 month old
Sprague Dawley rats and placed in modified Krebs solution (118.5 mM
NaCl, 4.6 mM KCl, 1.2 mM MgSO.sub.4.7H.sub.2O, 1.2 mM
KH.sub.2PO.sub.4, 2.5 mM CaCl.sub.2.2H.sub.2O, 24.8 mM NaHCO.sub.3
and 10 mM glucose). The rings were then attached to an isometric
force transducer (Radnoti Inc., Monrovia, Calif.) and the data
recorded with a Ponemah physiology platform (Gould Instrument
systems, Inc., Valley View, Ohio) and placed in a 10 ml tissue bath
oxygenated (95% O.sub.2, 5% CO.sub.2) modified Krebs solution. The
tissues were adjusted to 1 gram resting tension and allowed to
stabilize for one hour before testing. The rings were tested by 5
.mu.l additions of 1.times.10.sup.-7 M norepinepherin (Sigma Co.,
St. Louis, Mo.) to a final concentration of about 1.times.10-9 M
and Carbachol, a muscarinic acetylcholine agonist (Sigma Co.) at
2.times.1.sup.-7 M final, to test the integrity of the rings. After
each test the rings were washed three times with fresh buffer, 5
minutes between washes and allowed to rest one hour. To test for
vasodilatation, the rings were contracted to two grams and allowed
to stabilize for fifteen minutes. Zsig37 was then added to 1, 2 or
3 of the 4 baths, without flushing, and tension on the rings was
recorded and compared to the control rings. The rings were then
tested for contraction with norepinepherin as described above.
Rings were tested at 323, 162, and 81 ng/ml zsig37 but a dose
response could not be determined. In order to evaluate the
statistical significance of the data, a contingency test was done
on all the zsig37 and control rings using dilation as a
determinant. Of 10 of the 12 rings tested with zsig37 vasodialated
as did 2 of the 7 controls. The Fisher exact P value is 0.045. It
was concluded that zsig37 induces vasodilatation in norepinepherin
contracted aortic rings.
EXAMPLE 12
[0144] Binding of zsig37 to Matrix Proteins
[0145] An ELISA (Enzyme-linked Immunosorbant Assay) was used to
measure binding of zsig37 to various matrix proteins and complement
C1q. The matrix proteins used were Bovine Collagen Type I (Becton
Dickinson, Lincoln Park, N.J.) laminin, vitronectin, fibronectin,
human collagen Types II, III, IV, V, VI (Chemicon International,
Temecula, Calif.). BSA V (Sigma Co.) was used as a negative
control. Just prior to use, the proteins were diluted in
2.times.PBS (Phosphate Buffered Saline, Sigma Co.) to 100 .mu.g/ml
and adjusted to pH 7.2 with 0.1 N NaOH. Each protein sample was
quadruplicate plated (100 .mu.l/well) into a 96 well plate. The
plate was allowed to dry overnight in a laminar flow hood and
washed 3 times with 400 .mu.l of 5 mg/ml BSA in 1.times.PBS and
blotted dry. Zsig37 was FITC labeled according to manufacturer's
instruction (Pierce, Rockford, Ill.). Into each well was added 100
.mu.l of 1.8 .mu.g/ml zsig37-FITC in 5% BSA, PBS. The plates were
incubated for 1.5 hours at room temperature then washed 3 time with
5% BSA, PBS. To each well was then added 100 .mu.l of 1:400 mouse
anti-FITC/Biotin (Sigma Co.). The plate was incubated 1.5 hours at
room temperature and washed 3 times with 5% BSA, PBS. The plate was
then incubated with 100 .mu.l of 1:1000 streptavidin/HRP (Amersham,
Piscataway, N.J.) for 1 hour and washed 3 times with 5% BSA, PBS.
The plate was then developed using Supersignal.RTM. Ultra (Pierce,
Rockford, Ill.) according to manufacturer's instruction. After
reacting for 1 minute, surplus liquid was removed from the plate by
inverting the plate and patting dry. The plate was exposed to X-ray
film (Kodak, Rochester, N.Y.).
[0146] The results of this screen indicate that only fibronectin
and the collagens I, II, III, V and VI bind significantly to
zsig37-FITC. Such binding was not seen with laminin, vitronectin,
collagen IV or the BSA control.
EXAMPLE 13
Specificity of Zsig37 Binding to Collagen Type VI
[0147] The ELISA assay for binding as described in Example 12 was
modified to quantitatively evaluate binding. Zsig37-FITC, in a
range of 0.4 to 4 .mu.g/ml, was bound to 10 .mu.g of collagen type
VI (Chemicon International) as described in above. The luminescence
from the Supersignal.RTM. reagent was read on a Wallac 1420 plate
reader (Wallac, Gaithersburg Md.) and the intensity used as a
quantitative measure of the zsig37-FITC bound to the ELISA
plate.
[0148] The binding of zsig37 to collagen type VI fits a typical
hyperbolic binding curve (FIG. 3a). The bound Zsig37-FITC plated at
0.4 .mu.g/ml can be competed off the collagen by the addition of
unlabeled Zsig37 in a range of 0.8 to 8 .mu.g/ml (FIG. 3b). These
data would indicate that binding is specific for domains on
collagen type VI and is concentration dependent.
EXAMPLE 14
[0149] Zsig37 Binding to Complement C1q
[0150] Zsig37-FITC at 0.2 .mu.g/ml was shown to bind to complement
C1q (Sigma Co.) at 0.1 to 10 .mu.g/ml by the method described above
in Example 13, (FIG. 4). The amount of binding is concentration
dependent and saturable.
EXAMPLE 15
[0151] Complement Inhibition by Zsig37
[0152] Complement assays were performed in 96 well round &
bottom plates. Gelatin Veronal buffer containing magnesium and
calcium (141 mM NaCl, 1.8 mM sodium barbitol, 3.1 mM Barbituric
acid, 0.1% bovine gelatin, 0.5 mM MgCl.sub.2 and 0.15 mM
CaCl.sub.2) was used for all serum and inhibitor dilutions as well
as erythrocyte suspensions. Fifty microliters of standardized human
Complement serum (Sigma Co.), diluted 1/37.5 (for a final dilution
of 1/150) was added to each well. The inhibitor was added in
triplicate, 50 .mu.l/well. The serum and inhibitor were incubated
for thirty minutes at room temperature. The assay was initiated by
the addition of 100 .mu.l of 2.times.10.sup.8/ml unsensitized sheep
erythrocytes (Colorado Serum Co., Denver, Colo.), sensitized sheep
erythrocytes, sensitized using the Hemolysin manufacturer's
protocol (BioWhittaker Inc., Walkersville, Md.) and rabbit
erythrocytes containing 16 mM EGTA, and 4 mM Mg.sup.++. A human
serum dilution series from 1/50 to 1/400 was also plated as an
activity control. Erythrocytes, lysed with distilled water and
diluted to 100, 75, 50, 25, and 12.5 percent lysis, were used to
quantify Complement percent lysis. The plate was sealed and
incubated at 37.degree. C. for 1 hour with mixing every 15 minutes.
The reaction was stopped by the addition of 220 mM EDTA, 20
.mu.l/well and the plates centrifuged at 1500.times.G for 10
minutes. One hundred microliters of supernatant was removed from
each well and transferred to a 96 well flat bottom plate for
analysis. The plate was read at 415 nM and percent lysis was
calculated.
[0153] Zsig37 was effective in inhibiting the classical pathway
with both sensitized and unsensitized sheep erythrocytes (FIG. 5).
There was no apparent inhibition of the alternate pathway tested
with rabbit erythrocytes and EGTA. The mechanism of inhibition is
undetermined but because C1q binds zsig37, C1 is the most likely
target.
EXAMPLE 16
[0154] Inhibition by Zsig37 of Platelet Collagen Activation
[0155] Blood was drawn from healthy volunteers into tubes
containing sodium citrate, maintained at room temperature and used
within four hours of drawing. Whole blood was analyzed for platelet
activation using a Chrono-Log 560A Whole Blood Lumi-Aggregometer
(Chrono-Log Corp., Haverton, Pa.) according to manufacturer's
instructions. For each test point, 500 .mu.l of blood was added to
a reaction tube containing a stir bar and 500 .mu.l of isotonic
saline containing zsig37 at concentrations from 0 to 20 .mu.g/ml.
The mixture was incubated for four minutes followed by platelet
activation initiated by the addition of 51 .mu.l of 1 mg/ml
cross-linked collagen (Chrono-Log Corp.) to the blood/zsig37
mixture. Inhibition of activation by ADP (final concentration 10
.mu.M), and thrombin (final concentration 1U/ml) was tested in a
similar way.
[0156] Inhibition of collagen-mediated platelet activation by
zsig37 shows a dose dependent relationship between 5 and 20
.mu.g/ml (FIG. 6a). The inhibition is selective for collagen
activation and has no effect on activation stimulated by ADP or
thrombin (FIG. 6b). Collagen activation was not inhibited by
another complement C1q related protein zsig39 (co-pending U.S.
patent application Ser. No. 09/140,804).
EXAMPLE 17
[0157] Stimulation of SK5 Fibroblast Growth by Zsig37
[0158] Human fibronectin (25 ug/ml, GIBCO BRL, Gaithersburg, Md.)
was plated into 96 well plates (Costar, Pleasanton, Calif.) at 100
.mu.l/well and allowed to dry in a laminar hood overnight. Human
SK5 fibroblasts in DMEM (Gibco) containing 10% Fetal Bovine
Serum--low endotoxin (Hyclone, Logan, Utah) were plated at 5000
cells/well into the fibronectin-coated plates and incubated at
37.degree. C., 5% CO.sub.2 for 2 to 3 days. The number of cells per
plate was adjusted to achieve non-confluence. Cells were then
washed twice with serum-free DMEM hi glucose (Gibco) and serum
starved by growing in serum-free DMEM hi glucose for 24 hours.
Zsig37 was added to the wells in triplicate, at concentrations of
312.2 ng/ml to 10,000 ng/ml in 100 .mu.l DMEM. The cells were then
incubated for 48 hours at 37.degree. C., 5% CO.sub.2. Cell
proliferation was tested by adding 15 Iul MTT dye solution
(CellTiter96.TM. kit, Promega) to each well. The plate was
incubated 4 hours at 37.degree. C., 5% CO.sub.2 and the reaction
was stopped with Solublization/Stop solution (CellTiter96.TM. kit,
Promega) according to the manufacturer's instructions. The plate
was incubated for 1 hour to solubilize formazan crystals and the
absorbance was measured at 570 nm with a reference at 650 nm using
an ELISA plate reader.
[0159] The results (FIG. 7) show a dose dependent increase in SK5
fibroblast number over the range of zsig37 concentrations tested.
These concentrations were within the range of values seen for the
mitogenic effects of the fibrinogen b chain (Gray, et al, Am J.
Respir. Cell Mol. Biol. 12, 684,1995 and Gray, et al, J. Biol.
Chem. 270, 26602, 1995) and for fibroblast cell adhesion to plated
C1q (Bordin, and Ghebrehiwet, J. Immun. 145:2520, 1990) both of
which are believed to interact with cell surface calreticulin.
EXAMPLE 18
[0160] Zsiq37 Anti-Sera Production
[0161] Rabbit polyclonal anti-sera was prepared by immunizing two
female New Zealand white rabbits with zsig37-CEE purified from BHK
cells. The protein was conjugated to the carrier protein keyhole
limpet hemocyanin (KLH) with gluteraldehyde. The rabbits were each
given an initial intraperitoneal (ip) injection of 200 .mu.g of
peptide in Complete Freund's Adjuvant followed by booster ip
injections of 100 .mu.g peptide in Incomplete Freund's Adjuvant
every three weeks. Seven to ten days after the administration of
the second booster injection, the animals were bled and the serum
was collected. The animals were then boosted and bled every three
weeks.
EXAMPLE 19
[0162] Detection of FITC Tagged Zsiq37 Protein Binding in
Tissues
[0163] FITC tagged Zsig37 protein binding in tissues was detected
as follows:
[0164] Paraffin embedded and sectioned human tissues or mouse
embryos on slides were obtained either from commercial sources
(i.e. DAKO Corporation, Carpinteria, Calif.; BioGenex, San Ramon,
Calif.; Novagen, Madison, Wis.; and Biomeda, Foster City, Calif.)
or in house. The human tissue sections included adrenal gland,
brain, heart, small intestine, large intestine, kidney, liver,
lung, ovary, pancreas, prostate, spleen, stomach, testis, thyroid,
and uterus. The mouse embryo sections were from the 16 day
stage.
[0165] The tissue sections were dewaxed using standard conditions
of 3.times.5 minutes in xylene, 4 minutes in 100% ethanol (EtOH), 3
minutes in 100% EtOH, and 2 minutes in 95% EtOH. The tissue
sections were then subjected to a 20 minute antigen retrieval
process at 94.degree. C. according to-the manufactures instructions
(DAKO Corporation), followed by a 20 minute 0.01% Pepsin/0.2 N HCl
digest. The tissue sections were rinsed twice in dH.sub.2O and once
in PBS/0.05% Tween 20 (Sigma, St. Louis, Mo.) buffer and then
blocked for 45 minutes with 1.times.PBS/5% BSA/5% nonfat dry milk
(Carnation, Los Angeles, Calif.). This was followed by an
avidin/biotin blocking step done according to the manufacturers
instructions (Vector Laboratories, Inc., Burlingame, Calif.). The
tissue sections were washed 3 times in 1.times.PBS/0.05% Tween 20
buffer and then incubated with appropriate concentration of FITC
tagged Zsig37 protein in PBS/5% BSA for 45-60 minutes. After
washing the tissue sections 3 times in 1.times.PBS/0.05% Tween 20,
they were incubated with a 1:400 dilution of anti-FITC (mo) MAb
Biotin conjugate (Sigma) for 30-60 minutes, washed 3 times in
PBS/0.05% Tween 20 and then incubated for 30-60 minutes with a
1:500 dilution of Streptavidin-FITC (NEN Life Science Products,
Boston, Mass.) followed by 2 washes in 1.times.PBS/0.05% Tween 20
buffer and 1 wash in 1.times.PBS without Tween 20. The tissues
sections were then mounted with an antifade medium containing 0.5
.mu.g/ml propidium iodode as counterstain.
[0166] Significant binding was seen to vessel walls and fine
fibrous connective type tissues such as collagenous matrix in the
majority of the human tissues and embryo sections studied.
EXAMPLE 20
[0167] Zsiq37 in the Rabbit Carotid Artery Injury Model
[0168] Zsig37 was administered in a modified rabbit carotid artery
injury model (Folts et al., Circulation 79:116-24, 1989 and Golino
et al., Thrombosis and Haemostasis 67:302-5, 1992) to determine the
degree of protection offered in preventing vascular occlusion
following a crush injury.
[0169] Thirty four male New Zealand White rabbits, approximately
3-6 months old (R&R Rabbitry, Stanwood, Wash.) were into two
groups. Fifteen rabbits received doses of zsig37 ranging from
2-13.5 .mu.g/kg and 19 control rabbist were injected with PBS or
equivalent amounts of PBS or zsig39, another adipocyte complement
related protein (WO99/10492). The rabbits were anesthetized with
ketamine (50 mg/kg, IM) and maintained on halothane inhalation
anesthesia for the duration of the study. The hair was shaved from
the ears and neck and an angiocatheter was placed in the marginal
ear vein for IV support. A midline incision was made in the neck
and the carotid artery was accessed. Approximately 5 cm of the
common carotid artery proximal to the internal/external bifurcation
was exposed via blunt dissection away from the surrounding tissue
and any visible side branches were cauterized. A flow probe
(Transonic Systems, Inc., Ithaca N.Y.) was placed distal to the
anticipated injury site and a baseline blood flow was established.
A 2.5-3.0 cm section of the vessel was then isolated from
circulation using atraumatic vascular clamps. Following removal of
the blood from the vessel segment, 0.4 ml of zsig37 in 0.9% sodium
chloride or 0.04 ml 0.9% sodium chloride as a control, was injected
into the empty vessel segment using a 30G needle. The vessel was
left undisturbed for a 5 minute pre-injury treatment. A 1.0 cm
crush injury was then inflicted into the center of the vessel
segment using a guarded hemostat and left undisturbed for 10
minutes. The vessel clamps were then removed and blood flow
reestablished. Blood flow was monitored continuously for 60 minutes
after which time the rabbits were euthanized and the vessel excised
for histological analysis.
[0170] No dose dependency was seen at these concentrations. A meta
analysis of all zsig37 doses resulted in significant increase in
time patent when compared to controls in an unpaired t-test
(P=0.019).
[0171] The mean percent time patent for the combined groups of
negative control animals, as determined from blood flow tracings,
was 13.5% with a standard error of .+-.1.7%. The mean percent time
patent for the combined zsig37 treated groups of animals, as
determined from blood flow tracings, was 37.2% with a standard
error of .+-.10.3%.
[0172] In a second series of experiments, fluoresceinated zsig37
was used in the injured carotid artery model. Male, New Zealand
White rabbits were anesthetized as above. Via an incision in the
neck, the carotid artery was exposed and approximately 5 cm of the
vessel isolated from the surrounding consecutive tissue. Blood was
evacuated from the isolated segment and atraumatic vascular clips
were applied. Approximately 0.05 ml of fluoreceinated zsig37
(concentration 100 .mu.g/ml) was injected into the isolated segment
to completely fill the vessel using a 30 g needle. After an
exposure period of 5 minutes, the vessel was injured and the
exposure continued for another 110 minutes before the clips were
removed and blood flow reestablished. The animals were euthanized
as described above at 1, 10, and 60 minutes post-reestablishment of
blood flow and the vessels collected and formalin fixed for
histological evaluation.
[0173] Labeled zsig37 preferentially bound to receptors in the
media of the injured vessels. Labeled zsig37 did not bind to areas
of the vessel that were uninjured. The time of blood flow prior to
vessel collection does not appear to effect the amount of zsig37
that remains bound to the tissue, i.e., there was no difference in
the amount of labeled zsig37 bound to the tissues in the 1 minute
vs. the 60 minute collection time point. This may indicate that
zsig37 tightly binds to the injured vessel and is not washed off by
the reestablished blood flow.
[0174] The effect of zsig37 on blood flow dynamics following
vascular injury in a rabbit iliac artery crush injury/stenosis
model was also evaluated. Young adult male New Zealand White
rabbits were anesthetized as described above. Via an abdominal
incision, the aorto-iliac bifurcation was exposed and each iliac
freed of surrounding tissues and the main branches ligated. Each
iliac was instrumented with an ultrasound flow probe to monitor
blood flow through the vessel. Based on blood flow data, one iliac
was selected to be used for the injury and the other was
catheterized for delivery of the test sample. Rabbits were divided
into dose groups of 6 animals/group. Test sample doses containing
zsig37 increased in half-log increments from 3-1000 .mu.g/kg over
the selected infusion period. The test samples infusion was
initiated followed by creation of a critical stenosis that reduced
blood flow through the vessel by approximately 50%. After creation
of the stenosis and a period of blood flow stabilization, the
vessel was injured by crushing the vessel between the jaws of a
smooth needle holder. The infusion was continued post-injury for a
set period of time, 10-20 minutes. Blood flow through the injured
vessel was monitored for 60 minutes post-injury. The animals were
euthanized at he conclusion of the study period. The lower section
of the abdominal aorta and each iliac were collected and formalin
fixed for histological evaluation.
[0175] Blood flow parameters determined from the flow tracings,
included mean flow post-stenosis, mean flow post-injury, and time
the vessel remained patent. This data suggests there is a tendency
for zsig37 to promote increased patency time with increased dose up
to 300 .mu.g/kg/ over a 60 minute period.
EXAMPLE 21
[0176] Relaxation of Serotonin-Induced Rat Aortic Ring
Contractions
[0177] Male, Sprague-Dawley rats, approximately 3 months of age,
were lightly anesthetized with CO.sub.2 and then decapitated. The
thoracic aorta was then rapidly removed and placed in a modified
Kreb's-Henseleit buffer (NaCl, 118.2 mM; KCl, 4.6 mM; CaCl.sub.2,
2.5 mM; MgSO.sub.4, 1.2 mM; NaHCO.sub.3, 24.8 mM; KH.sub.2PO.sub.4,
1.2 mM; and glucose, 10.0 mM). From each rat, four 2-3 mm aortic
ring sections were cut after discarding the rough end of the aorta.
In some experiments the endothelium was denuded, prior to cutting
ring sections, by rubbing the lumen of the aorta along a 21 gauge
needle. Denudation of the endothelium was verified by the addition
of the acetylcholine analogue, carbachol, prior to determining
zsig37 concentration-dependent responses. In the absence of the
endothelium, carbachol does not vasorelax constricted vascular ring
sections.
[0178] The rings were fixed and connected to force displacement
transducers in oxygenated (95% O.sub.2, 5% CO.sub.2), jacketed,
glass organ baths kept at 30.degree. C. in modified
Kreb's-Henseleit buffer, pH 7.4. Resting tension was set at 1 gm,
and continually re-adjusted to 1 gm over a 1 hour incubation
period. Fresh oxygenated modified Kreb's-Henseleit buffer was added
to the baths every fifteen minutes during the resting incubation
period. At the end of the 1 hour incubation, the ring sections were
contracted by the addition of 10 .mu.M serotonin. After maximum
contraction had been reached, approximately 15-20 minutes after the
addition of the serotonin, cumulative concentration response curves
for zsig37 were constructed. Zsig37 was added to 5 ml baths in
volumes from 5 up to 150 .mu.ls, for final concentrations ranging
from 1 ng/ml up to 40 .mu.g/ml. Viability of the ring sections was
verified at the end of the concentration response by the addition
of forskolin (2.5 .mu.M or 25 .mu.M) or nitroglycerin (22
.mu.M).
[0179] Addition of zsig37 induced a concentration-dependent
vasorelaxation of serotonin-contracted rat aortic sections with and
without an intact endothelium. Relaxation in response of zsig37 was
first observed at concentrations above 100 ng/ml. Relaxation was
observed approximately 30-60 seconds after the additions of each
zsig37 concentration to the bath, and relaxation responses
plateaued within 3-5 minutes after the addition of zsig37. The
character of the relaxation response to zsig37 indicates that the
vasorelaxation is a receptor-second messenger mediated event.
Additionally, the ability of zsig37 to vasorelax
endothelium-denuded aortic sections indicates that zsig37 acts
directly on the smooth muscle cells to elicit the vasorelaxant
response.
EXAMPLE 22
[0180] Identification of Cells Expressing zsiq37 Receptor Using in
situ Hybridization
[0181] Specific human tissues were isolated and screened for zsig37
expression by in situ hybridization. Various human tissues
prepared, sectioned and subjected to in situ hybridization included
aorta, heart, lymph node, placenta. Prostate, salivary gland, skin,
and testis. The tissues were fixed in 10% buffered formalin
(Surgipath, Richmond, Ill.), and embedded in parapalst X-tra
(Oxford Scientific, St. Louis, Mo.), and sectioned at 5 .mu.m with
a Reichart-Jung 2050 microtome (Leica Instruments GmbH, Nussloch,
Germany). Tissues were sectioned at 4 to 8 microns. Tissues were
prepared using a standard protocol ("Development of nono-isopotic
in situ hybridization", Laboratory of Experimental Pathology,
National Institute of Environmental Health Sciences, Research Park
Triangle, N.C.). Briefly, tissue sections were deparaffinized with
HistoClear (National Diagnostics, Atlanta, Ga.) and then dehydrated
with ethanol. Next the sections were digested with Proteinase K (50
.mu.g/ml) (Boehringer Mannheim, Indianapolis, Ind.) at 37.degree.
C. for 2 to 20 minutes. This step was followed by acetylation and
re-hydration of the tissues.
[0182] Three in situ probes generated by PCR were designed against
the human zsig37 sequence. Two sets of oligonucleotide primers were
designed to generate probes for separate regions of the zsig37
cDNA: (1) Oligonucleotide ZC23,689 (SEQ ID NO: 45) and ZC23,694
(SEQ ID NO: 46) were used to generate a 414 bp probe for zsig37;
(2) ZC23,703 (SEQ ID NO: 47) and ZC23,697 (SEQ ID NO: 48) were used
to generate a 896 bp probe for zsig37; (3) ZC24,441 (SEQ ID NO: 49)
and ZC24,442 (SEQ ID NO: 50) were used to generate a 290 bp probe
for zsig37. The antisense oligo from each set also contained the
working sequence for the T7 RNA polymerase promoter to allow for
easy transcription of antisense RNA probes from these products. The
PCR products were purified by Qiagen spin columns (Qiagen, Inc.,
Chatsworth, Calif.) followed by phenol/chloroform extraction and
ethanol precipitation. Probes were subsequently labeled with
digoxigenin (Boehringer) or biotin (Boehringer) using an in vitro
transcription system (Promega Corp., Madison, Wis.) according to
the manufacturer's instructions.
[0183] In situ hybridization was performed with a digoxigenin- or
biotin-labeled zsig37 probe as described above. The probe was added
to the slides at a concentration of 1 to 5 pmol/ml for 12 to 16
hours at 50-60.degree. C. Slides were subsequently washed in
2.times.SSC and 0.1.times.SSC at 50-55.degree. C. Slides were
subsequently washed in 2.times.SSC and 0.1.times.SSC at
50-55.degree. C. The signals were amplified using tyramide signal
amplification (TSA in situ indirect kit, NEN, Boston, Mass.) and
visualized with a Vector Red substrate kit (Vector Laboratories,
Burlingame, Calif.) according to manufacturer's instructions. The
slides were then counter-stained with hematoxylin (Vector
Laboratories).
[0184] Positive signals were seen in the human aorta, heart,
prostate, salivary gland, and testis. The positive-staining cells
appeared to be endothelial cells of small diameter vessels in the
advantitia surrounding the aorta, mesothelial cells overlying the
epicardium, acinar cells of the salivary gland and scattered
mononuclear cells, trophoblasts of the placenta, epithelial cells
of the prostate and stratified epithelium of the seminiferous
tubules of testis.
EXAMPLE 23
[0185] SEC-MALLS Analysis of Zsig37
[0186] Zsig37 contains a N-terminal collagen-like domain as well as
a C-terminal globular region having homology to the tumor necrosis
factor family and like other such proteins, zsig37 is expected to
multimerize. Purified zsig37 analyzed using an ESI-ion trap mass
spectrometer (Finnigan Matt, San Jose, Calif.) indicated the
presence of species approximating trimers and 9mers, which was an
unexpected result when compared to other homologous proteins.
Peptide mapping of zsig37 using LC-MS/MS on an ESI-ion trap mass
spectrometer (Finnigan Matt) revealed that several cysteine
residues were modified with an S-cysteinyl group. It may be that
modification of key cysteine residues in the zsig37 protein during
fermentation with free cysteine in the media is preventing proper
oligomeric association of this molecule.
[0187] To learn more, a comparison of reduced and nonreduced zsig37
was made using a Biosep S-300 size exclusion column at 1.0
ml/minute (7.8.times.3000 mm; Phenomenex, Torrance, Calif.) on a HP
1050 HPLC (Hewlett Packard, Heidleberg, Germany). The HP 1050 was
coupled to light scattering and refractive index detectors,
miniDAWN and Optilab DSP, (Waytt Technology, Santa Barbara, Calif.)
for on-line SEC-MALLS.
[0188] One milligram of recombinant zsig37 (1.0 mg/ml) was added to
TCEP at a 10:1 mol/mol ratio of TCEP to zsig37 and kept at room
temperature for 70 minutes. Sixty microliters of the reduced zsig37
was injected for SEC-MALLS analysis and the remainder of the
reduced zsig37 was dialyzed in 0.5-3.0 ml Slide-A-Lyzer cassettes,
10K MWCO (Pierce, Rockford, Ill.) with stirring against PBS, pH 7.4
with three buffer changes as follows: 1 liter PBS at room
temperature for 4 hours, 1 liter PBS at 4.degree. C. overnight, and
1 liter PBS at room temperature for 4 hours.
[0189] Following dialysis, oxidation was allowed to continue at
4.degree. C. The oxidation was monitored by SEC-MALLS analysis of
aliquots taken at three time points, T=0 hours, T=24 hours, and
T=96 hours. Molecular weight values were determined using the
LS-RI, two-detector method.
[0190] Analysis of the reduced, dialyzed recombinant zsig37 seems
to initially indicate the formation of hexamers and 18mers as
detected-by SEC-MALLS which is more consistent with the oligomeric
states observed in homologs. These forms were also active in in
vitro assays.
EXAMPLE 24
[0191] Zsiq37 Binding to Monocytes
[0192] CD14 positive monocytes were isolated from frozen peripheral
blood aphaeresis product using a positive selection method with
Miltenyi beads (Miltenyi Biotec Auburn, Calif.). Purified cells
were greater than 80% CD14 positive via FACS staining. Cells were
resuspended at 1.times.10.sup.6 cells/ml in RPMI+10% fetal bovine
serum (FBS) and plated in 100 mm tissue culture dishes, 5 ml/plate.
Recombinant human y interferon was added at 100 ng/ml and the cells
were incubated at 5% CO.sub.2, 37.degree. C. for 48 hours.
[0193] The cells were removed from the plates by nonenzymatic
methods using both EDTA and scraping, concentrated by
centrifugation, resuspended in FACS staining buffer and aliquoted
at 500,000 cells/tube for staining. Nonactivated cells were
obtained by performing another CD14 selection with the same
apheresis product post 48 hours in .gamma. interferon. The cells
were incubated in varying concentrations of biotinylated zsig37
followed by Streptavidin PE. All blocking with "cold" zsig37 was
done on ice for 30 minutes. Unbound protein was removed by washing
once in FACS buffer. Binding was quantitated using a FACS caliber
instrument (Becton Dickinson, Lincoln Park, N.J.) and expressed as
a signal above secondary antibody only control. Monocyte activation
was verified by approximately a 1 log increase in ICAM-1 expression
in .gamma. interferon treated cells.
[0194] Zsig37 binding was detected in both activated and
nonactivated monocytes, with an increase in zsig37 binding observed
in .gamma. interferon-treated cells. Binding was detected down to
1.5 .mu.g/ml, the lowest concentration tested. At 15 .mu.g/ml,
binding was approximately 4 fold increased in activated cells. A
slight (approximately 10%) reduction in binding was seen in
activated cells only when pretreated with 70 fold excess "cold"
zsig37. Increased zsig37 binding in activated monocytes suggests
that the up-regulation of monocyte binding proteins/receptors for
zsig37 by inflammatory cytokines. This could potentially result in
zsig37 involvement in monocyte phagocytosis, microbial killing, and
cellular cytotoxicity. Following the two days in culture, there are
macrophages present in the culture and zsig37 may be binding
preferentially to this subset of cells. There are no good
macrophage markers available to determine if this is occurring.
Zsig37 also bound to a mouse monocyte/macrophage line, RAW 264.7
(ATCC No. CRL-2278), indicating macrophage specificity.
EXAMPLE 25
[0195] Indium Labeled zsiq37
[0196] A ten-fold molar excess of DTPA (diethylenetriamine
pentaacetic acid), a chelating agent, was reacted with zsig37. The
resultant product was delivered into a 10,000 MWCO Slide-A-Lyzer
dialysis cassette, equilibrated in a 0.1 M Hepes buffer, pH 7.0 for
a minimum of 4 hours or overnight, with at least one buffer
exchange. The zsig 37/DTPA was removed from the cassette and
reacted with .sup.111In at 150 .mu.Ci/mg at room temperature for 30
minutes with rocking. The zsig37/.sup.111In product was desalted to
remove any unbound .sup.111In and Hepes buffer using a PD-10 column
equilibrated with 0.1 M Acetate pH 6.0, or 120 mM NaCl. Five
hundred microliter fractions were collected and monitored for
radioactivity on a gamma counter. The fractions containing protein
(radiation) were pooled and 500 mM Na Phosphate pH 7.4 was added to
the pooled volume to a final concentration of 10 mM.
[0197] .sup.111In-labeled zsig37 was administered at 30, 100, 300
and 1000 .mu.g/kg in a modified rabbit carotid artery injury model
as described above. .sup.111In-labeled zsig37 was detected in the
highest concentrations at the site of the injury and in liver and
kidney.
[0198] From the foregoing, it will be appreciated that, although
specific embodiments of the invention have been described herein
for purposes of illustration, various modifications may be made
without deviating from the spirit and scope of the invention.
Accordingly, the invention is not limited except as by the appended
claims.
Sequence CWU 1
1
55 1 2769 DNA Homo sapiens CDS (171)...(1013) 1 gaattcgaat
tcctttgttt ccactgggac ggaatcggag ctctggaggc tgggctggcc 60
aagcgccccg aaggcccgat gcctgacggc tcatgcggcc tccttgtttg cagggcctgg
120 gcaaaaattt acactgagtc ccactcttcg ctccagggcc cggcaggaag atg ggc
176 Met Gly 1 tcc cgt gga cag gga ctc ttg ctg gcg tac tgc ctg ctc
ctt gcc ttt 224 Ser Arg Gly Gln Gly Leu Leu Leu Ala Tyr Cys Leu Leu
Leu Ala Phe 5 10 15 gcc tct ggc ctg gtc ctg agt cgc gtg ccc cat gtc
cag ggg gaa cag 272 Ala Ser Gly Leu Val Leu Ser Arg Val Pro His Val
Gln Gly Glu Gln 20 25 30 cag gag tgg gag ggg act gag gag ctg ccg
tcc cct ccg gac cat gcc 320 Gln Glu Trp Glu Gly Thr Glu Glu Leu Pro
Ser Pro Pro Asp His Ala 35 40 45 50 gag agg gct gaa gaa caa cat gaa
aaa tac agg ccc agt cag gac cag 368 Glu Arg Ala Glu Glu Gln His Glu
Lys Tyr Arg Pro Ser Gln Asp Gln 55 60 65 ggg ctc cct gct tcc cgg
tgc ttg cgc tgc tgt gac cct ggt acc tcc 416 Gly Leu Pro Ala Ser Arg
Cys Leu Arg Cys Cys Asp Pro Gly Thr Ser 70 75 80 atg tac ccg gcg
acc gcc gtg ccc cag atc aac atc act atc ttg aaa 464 Met Tyr Pro Ala
Thr Ala Val Pro Gln Ile Asn Ile Thr Ile Leu Lys 85 90 95 ggg gag
aag ggt gac cgc gga gat cga ggc ctc caa ggg aaa tat ggc 512 Gly Glu
Lys Gly Asp Arg Gly Asp Arg Gly Leu Gln Gly Lys Tyr Gly 100 105 110
aaa aca ggc tca gca ggg gcc agg ggc cac act gga ccc aaa ggg cag 560
Lys Thr Gly Ser Ala Gly Ala Arg Gly His Thr Gly Pro Lys Gly Gln 115
120 125 130 aag ggc tcc atg ggg gcc cct ggg gag cgg tgc aag agc cac
tac gcc 608 Lys Gly Ser Met Gly Ala Pro Gly Glu Arg Cys Lys Ser His
Tyr Ala 135 140 145 gcc ttt tcg gtg ggc cgg aag aag ccc atg cac agc
aac cac tac tac 656 Ala Phe Ser Val Gly Arg Lys Lys Pro Met His Ser
Asn His Tyr Tyr 150 155 160 cag acg gtg atc ttc gac acg gag ttc gtg
aac ctc tac gac cac ttc 704 Gln Thr Val Ile Phe Asp Thr Glu Phe Val
Asn Leu Tyr Asp His Phe 165 170 175 aac atg ttc acc ggc aag ttc tac
tgc tac gtg ccc ggc ctc tac ttc 752 Asn Met Phe Thr Gly Lys Phe Tyr
Cys Tyr Val Pro Gly Leu Tyr Phe 180 185 190 ttc agc ctc aac gtg cac
acc tgg aac cag aag gag acc tac ctg cac 800 Phe Ser Leu Asn Val His
Thr Trp Asn Gln Lys Glu Thr Tyr Leu His 195 200 205 210 atc atg aag
aac gag gag gag gtg gtg atc ttg ttc gcg cag gtg ggc 848 Ile Met Lys
Asn Glu Glu Glu Val Val Ile Leu Phe Ala Gln Val Gly 215 220 225 gac
cgc agc atc atg caa agc cag agc ctg atg ctg gag ctg cga gag 896 Asp
Arg Ser Ile Met Gln Ser Gln Ser Leu Met Leu Glu Leu Arg Glu 230 235
240 cag gac cag gtg tgg gta cgc ctc tac aag ggc gaa cgt gag aac gcc
944 Gln Asp Gln Val Trp Val Arg Leu Tyr Lys Gly Glu Arg Glu Asn Ala
245 250 255 atc ttc agc gag gag ctg gac acc tac atc acc ttc agt ggc
tac ctg 992 Ile Phe Ser Glu Glu Leu Asp Thr Tyr Ile Thr Phe Ser Gly
Tyr Leu 260 265 270 gtc aag cac gcc acc gag ccc tagctggccg
gccacctcct ttcctctcgc 1043 Val Lys His Ala Thr Glu Pro 275 280
caccttccac ccctgcgctg tgctgacccc agggctcagc accaggctga ccccaccgcc
1103 tcttccccga tccctggact ccgactccct ggctttggca ttcagtgaga
cgccctgcac 1163 acacagaaag ccaaagcgat cggtgctccc agatcccgca
gcctctggag agagctgacg 1223 gcagatgaaa tcaccagggc ggggcacccg
cgagaaccct ctgggacctt ccgcggccct 1283 ctctgcacac atcctcaagt
gaccccgcac ggcgagacgc gggtggcggc agggcgtccc 1343 agggtgcggc
accgcggctc cagtccttgg aaataattag gcaaattcta aaggtctcaa 1403
aaggagcaaa gtaaaccgtg gaggacaaag aaaagggttg ttatttttgt ctttccagcc
1463 agcctgctgg ctcccaagag agaggccttt tcagttgaga ctctgcttaa
gagaagatcc 1523 aaagttaaag ctctggggtc aggggagggg ccgggggcag
gaaactacct ctggcttaat 1583 tcttttaagc cacgtaggaa ctttcttgag
ggataggtgg accctgacat ccctgtggcc 1643 ttgcccaagg gctctgctgg
tctttctgag tcacagctgc gaggtgatgg gggctggggc 1703 cccaggcgtc
agcctcccag agggacagct gagccccctg ccttggctcc aggttggtag 1763
aagcagccga agggctcctg acagtggcca gggacccctg ggtcccccag gcctgcagat
1823 gtttctatga ggggcagagc tcctggtaca tccatgtgtg gctctgctcc
acccctgtgc 1883 caccccagag ccctgggggg tggtctccat gcctgccacc
ctggcatcgg ctttctgtgc 1943 cgcctcccac acaaatcagc cccagaaggc
cccggggctt tggcttctgt tttttataaa 2003 acacctcaag cagcactgca
gtctcccatc tcctcgtggg ctaagcatca ccgcttccac 2063 gtgtgttgtg
ttggttggca gcaaggctga tccagacccc ttctgccccc actgccctca 2123
tccaggcctc tgaccagtag cctgagaggg gctttttcta ggcttcagag caggggagag
2183 ctggaagggg ctagaaagct cccgcttgtc tgtttctcag gctcctgtga
gcctcagtcc 2243 tgagaccaga gtcaagagga agtacacatc ccaatcaccc
gtgtcaggat tcactctcag 2303 gagctgggtg gcaggagagg caatagcccc
tgtggcaatt gcaggaccag ctggagcagg 2363 gttgcggtgt ctccgcggtg
ctctcgccct gcccatggcc accccagact ctgatctcca 2423 ggaaccccat
agcccctctc cacctcaccc catgttgatg cccagggtca ctcttgctac 2483
ccgctgggcc cccaaacccc cgctgcctct cttccttccc cccatccccc acctggtttt
2543 gactaatcct gcttccctct ctgggcctgg ctgccgggat ctggggtccc
taagtccctc 2603 tctttaaaga acttctgcgg gtcagactct gaagccgagt
tgctgtgggc gtgcccggaa 2663 gcagagcgcc acactcgctg cttaagctcc
cccagctctt tccagaaaac attaaactca 2723 gaattgtgtt ttcagcaaaa
aaaaaaaaaa aaaaaagggc ggccgc 2769 2 281 PRT Homo sapien 2 Met Gly
Ser Arg Gly Gln Gly Leu Leu Leu Ala Tyr Cys Leu Leu Leu 1 5 10 15
Ala Phe Ala Ser Gly Leu Val Leu Ser Arg Val Pro His Val Gln Gly 20
25 30 Glu Gln Gln Glu Trp Glu Gly Thr Glu Glu Leu Pro Ser Pro Pro
Asp 35 40 45 His Ala Glu Arg Ala Glu Glu Gln His Glu Lys Tyr Arg
Pro Ser Gln 50 55 60 Asp Gln Gly Leu Pro Ala Ser Arg Cys Leu Arg
Cys Cys Asp Pro Gly 65 70 75 80 Thr Ser Met Tyr Pro Ala Thr Ala Val
Pro Gln Ile Asn Ile Thr Ile 85 90 95 Leu Lys Gly Glu Lys Gly Asp
Arg Gly Asp Arg Gly Leu Gln Gly Lys 100 105 110 Tyr Gly Lys Thr Gly
Ser Ala Gly Ala Arg Gly His Thr Gly Pro Lys 115 120 125 Gly Gln Lys
Gly Ser Met Gly Ala Pro Gly Glu Arg Cys Lys Ser His 130 135 140 Tyr
Ala Ala Phe Ser Val Gly Arg Lys Lys Pro Met His Ser Asn His 145 150
155 160 Tyr Tyr Gln Thr Val Ile Phe Asp Thr Glu Phe Val Asn Leu Tyr
Asp 165 170 175 His Phe Asn Met Phe Thr Gly Lys Phe Tyr Cys Tyr Val
Pro Gly Leu 180 185 190 Tyr Phe Phe Ser Leu Asn Val His Thr Trp Asn
Gln Lys Glu Thr Tyr 195 200 205 Leu His Ile Met Lys Asn Glu Glu Glu
Val Val Ile Leu Phe Ala Gln 210 215 220 Val Gly Asp Arg Ser Ile Met
Gln Ser Gln Ser Leu Met Leu Glu Leu 225 230 235 240 Arg Glu Gln Asp
Gln Val Trp Val Arg Leu Tyr Lys Gly Glu Arg Glu 245 250 255 Asn Ala
Ile Phe Ser Glu Glu Leu Asp Thr Tyr Ile Thr Phe Ser Gly 260 265 270
Tyr Leu Val Lys His Ala Thr Glu Pro 275 280 3 247 PRT Homo sapien 3
Met Leu Leu Leu Gln Ala Leu Leu Phe Leu Leu Ile Leu Pro Ser His 1 5
10 15 Ala Glu Asp Asp Val Thr Thr Thr Glu Glu Leu Ala Pro Ala Leu
Val 20 25 30 Pro Pro Pro Lys Gly Thr Cys Ala Gly Trp Met Ala Gly
Ile Pro Gly 35 40 45 His Pro Gly His Asn Gly Thr Pro Gly Arg Asp
Gly Arg Asp Gly Thr 50 55 60 Pro Gly Glu Lys Gly Glu Lys Gly Asp
Ala Gly Leu Leu Gly Pro Lys 65 70 75 80 Gly Glu Thr Gly Asp Val Gly
Met Thr Gly Ala Glu Gly Pro Arg Gly 85 90 95 Phe Pro Gln Thr Pro
Gly Arg Lys Gly Glu Pro Gly Glu Ala Ala Tyr 100 105 110 Met Tyr Arg
Ser Ala Phe Ser Val Gly Leu Glu Thr Arg Val Thr Val 115 120 125 Pro
Asn Val Pro Ile Arg Phe Thr Lys Ile Phe Tyr Asn Gln Gln Asn 130 135
140 His Tyr Asp Gly Ser Thr Gly Lys Phe Tyr Cys Asn Ile Pro Gly Leu
145 150 155 160 Tyr Tyr Phe Ser Tyr His Ile Thr Val Tyr Met Lys Asp
Val Lys Val 165 170 175 Ser Leu Phe Lys Lys Asp Lys Ala Val Leu Phe
Thr Tyr Asp Gln Tyr 180 185 190 Gln Glu Lys Asn Val Asp Gln Ala Ser
Gly Ser Val Leu Leu His Leu 195 200 205 Glu Val Gly Asp Gln Val Trp
Leu Gln Val Tyr Gly Asp Gly Asp His 210 215 220 Asn Gly Leu Tyr Ala
Asp Asn Val Asn Asp Ser Thr Phe Thr Gly Phe 225 230 235 240 Leu Leu
Tyr His Asp Thr Asn 245 4 30 DNA Artificial Sequence
Oligonucleotide ZC12447 4 atggggcacg cgactcagga ccaggccaga 30 5 19
DNA Artificial Sequence Oligonucleotide ZC695 5 gatttaggtg
acactatag 19 6 20 DNA Artificial Sequence Oligonucleotide ZC694 6
taatacgact cactataggg 20 7 20 DNA Artificial Sequence
Oligonucleotide ZC13210 7 aagcaccggg aagcagggag 20 8 20 DNA
Artificial Sequence Oligonucleotide ZC13588 8 cgggcacgta gcagtagaac
20 9 20 DNA Artificial Sequence Oligonucleotide ZC13532 9
gagagggctg aagaacaaca 20 10 20 DNA Artificial Sequence
Oligonucleotide ZC13641 10 aaggtggcga gaggaaagga 20 11 20 DNA
Artificial Sequence Oligonucleotide ZC13586 11 tgttcaccgg
caagttctac 20 12 20 DNA Artificial Sequence Oligonucleotide ZC13651
12 ctttgtcctc cacggtttac 20 13 20 DNA Artificial Sequence
Oligonucleotide ZC13622 13 tttcctctcg ccaccttcca 20 14 21 DNA
Artificial Sequence Oligonucleotide ZC13625 14 cttcggctgc
ttctaaccaa c 21 15 20 DNA Artificial Sequence Oligonucleotide
ZC13650 15 gtaaaccgtg gaggacaaag 20 16 21 DNA Artificial Sequence
Oligonucleotide ZC13859 16 gctgccaacc aacacaacca c 21 17 18 DNA
Artificial Sequence Oligonucleotide ZC13624 17 gcaggattag tcaaaacc
18 18 20 DNA Artificial Sequence Oligonucleotide ZC13531 18
aacatggggt gaggtggaga 20 19 20 DNA Artificial Sequence
Oligonucleotide ZC13587 19 tcctcgtggg ctaagcatca 20 20 20 DNA
Artificial Sequence Oligonucleotide ZC13623 20 atctccagga
accccatagc 20 21 18 DNA Artificial Sequence Oligonucleotide ZC14444
21 tctccaggaa ccccatag 18 22 18 DNA Artificial Sequence
Oligonucleotide ZC14445 22 gcaggattag tcaaaacc 18 23 843 DNA
Artificial Sequence Degenerate nucleotide sequence encoding zsig37
polypeptide 23 atgggnwsnm gnggncargg nytnytnytn gcntaytgyy
tnytnytngc nttygcnwsn 60 ggnytngtny tnwsnmgngt nccncaygtn
carggngarc arcargartg ggarggnacn 120 gargarytnc cnwsnccncc
ngaycaygcn garmgngcng argarcarca ygaraartay 180 mgnccnwsnc
argaycargg nytnccngcn wsnmgntgyy tnmgntgytg ygayccnggn 240
acnwsnatgt ayccngcnac ngcngtnccn carathaaya thacnathyt naarggngar
300 aarggngaym gnggngaymg nggnytncar ggnaartayg gnaaracngg
nwsngcnggn 360 gcnmgnggnc ayacnggncc naarggncar aarggnwsna
tgggngcncc nggngarmgn 420 tgyaarwsnc aytaygcngc nttywsngtn
ggnmgnaara arccnatgca ywsnaaycay 480 taytaycara cngtnathtt
ygayacngar ttygtnaayy tntaygayca yttyaayatg 540 ttyacnggna
arttytaytg ytaygtnccn ggnytntayt tyttywsnyt naaygtncay 600
acntggaayc araargarac ntayytncay athatgaara aygargarga rgtngtnath
660 ytnttygcnc argtnggnga ymgnwsnath atgcarwsnc arwsnytnat
gytngarytn 720 mgngarcarg aycargtntg ggtnmgnytn tayaarggng
armgngaraa ygcnathtty 780 wsngargary tngayacnta yathacntty
wsnggntayy tngtnaarca ygcnacngar 840 ccn 843 24 24 DNA Artificial
Sequence Oligonucleotide ZC15040 24 actcattcta gactagggct cggt 24
25 24 DNA Artificial Sequence Oligonucleotide ZC15033 25 atgaatggat
ccctggtcct gagt 24 26 7 PRT Artificial Sequence Glu-Glu affinity
tag peptide 26 Glu Glu Tyr Met Pro Met Glu 1 5 27 24 DNA Artificial
Sequence Oligonucleotide ZC15721 27 ctgtaggaat tcatgggctc ccgt 24
28 24 DNA Artificial Sequence Oligonucleotide ZC15035 28 attcatggat
ccgggctcgg tggc 24 29 20 DNA Artificial Sequence Oligonucleotide
ZC13006 29 ggctgtcctc taagcgtcac 20 30 19 DNA Artificial Sequence
Oligonucleotide ZC13007 30 aggggtcaca gggatgcca 19 31 6 PRT
Artificial Sequence Glu-Glu peptide 31 Gly Tyr Met Pro Val Asp 1 5
32 25 DNA Artificial Sequence Oligonucleotide ZC6768 32 gcaattaacc
ctcactaaag ggaac 25 33 21 DNA Artificial Sequence Oligonucleotide
ZC18297 33 tcctgaaagg cgagaaaggt g 21 34 20 DNA Artificial Sequence
Oligonucleotide ZC18298 34 ttccctgagt ctgagctagg 20 35 21 DNA
Artificial Sequence Oligonucleotide ZC18402 35 tccagagtga
ctggggaagt g 21 36 21 DNA Artificial Sequence Oligonucleotide
ZC18403 36 agtgacgagt tcgacaccta c 21 37 21 DNA Artificial Sequence
Oligonucleotide ZC18456 37 tgtgttccca ttcctggaca c 21 38 21 DNA
Artificial Sequence Oligonucleotide ZC18457 38 tccttccagc
tggctggaaa g 21 39 20 DNA Artificial Sequence Oligonucleotide
ZC18560 39 agaatgcagg gataggtcag 20 40 20 DNA Artificial Sequence
Oligonucleotide ZC18561 40 tcagaggatc ctgacagcag 20 41 21 DNA
Artificial Sequence Oligonucleotide ZC18687 41 tggacacgtg
agagggactt c 21 42 20 DNA Artificial Sequence Oligonucleotide
ZC18688 42 agcagtagaa cttcccagtg 20 43 2559 DNA Mus musculus CDS
(70)...(912) mouse ortholog 43 gaattcggat cctggaagag atgggattgt
tataggcgga aagagagaaa cccagagaag 60 tccaggaag atg ggc tcc tgt gca
cag gga ttc atg ctg gga tgc tgc ctg 111 Met Gly Ser Cys Ala Gln Gly
Phe Met Leu Gly Cys Cys Leu 1 5 10 ctg ctg gcc atc acc tgg ggc ccc
atc ctg agc ctt gtg cca cgc gtt 159 Leu Leu Ala Ile Thr Trp Gly Pro
Ile Leu Ser Leu Val Pro Arg Val 15 20 25 30 cag gag gaa caa cag gag
tgg gaa gag aca gag gag ctg cca tct cct 207 Gln Glu Glu Gln Gln Glu
Trp Glu Glu Thr Glu Glu Leu Pro Ser Pro 35 40 45 ctg gat cct gtg
aca agg cct gaa gaa aca cga gag aag tat agc cct 255 Leu Asp Pro Val
Thr Arg Pro Glu Glu Thr Arg Glu Lys Tyr Ser Pro 50 55 60 cgc cag
ggt gag gac ctc ccc act tct cgg tgc tac cga tgc tgt gac 303 Arg Gln
Gly Glu Asp Leu Pro Thr Ser Arg Cys Tyr Arg Cys Cys Asp 65 70 75
ccc agc aca cct gta tac cag aca att cct cca ccc cag atc aac atc 351
Pro Ser Thr Pro Val Tyr Gln Thr Ile Pro Pro Pro Gln Ile Asn Ile 80
85 90 acc atc ctg aaa ggc gag aaa ggt gac cga ggg gat cga ggc ctc
cag 399 Thr Ile Leu Lys Gly Glu Lys Gly Asp Arg Gly Asp Arg Gly Leu
Gln 95 100 105 110 ggg aag tac ggc aaa ata ggt tct aca ggt ccc agg
ggc cat gtt ggc 447 Gly Lys Tyr Gly Lys Ile Gly Ser Thr Gly Pro Arg
Gly His Val Gly 115 120 125 ccc aaa ggg cag aag gga tcc att gga gcc
cct ggg aac cac tgc aag 495 Pro Lys Gly Gln Lys Gly Ser Ile Gly Ala
Pro Gly Asn His Cys Lys 130 135 140 agc cag tac gca gcc ttc tcc gtg
ggc cgg aag aag gct ttg cac agc 543 Ser Gln Tyr Ala Ala Phe Ser Val
Gly Arg Lys Lys Ala Leu His Ser 145 150 155 aac gac tac ttc cag ccc
gtg gtc ttc gac acg gag ttt gtg aac ctc 591 Asn Asp Tyr Phe Gln Pro
Val Val Phe Asp Thr Glu Phe Val Asn Leu 160
165 170 tac aaa cac ttc aat atg ttc act ggg aag ttc tac tgc tat gtg
ccg 639 Tyr Lys His Phe Asn Met Phe Thr Gly Lys Phe Tyr Cys Tyr Val
Pro 175 180 185 190 ggc atc tac ttc ttc agc ctc aac gtg cac act tgg
aac cag aag gag 687 Gly Ile Tyr Phe Phe Ser Leu Asn Val His Thr Trp
Asn Gln Lys Glu 195 200 205 acg tac ctg cac atc atg aag aac gag gag
gag gtg gtg atc ctg tat 735 Thr Tyr Leu His Ile Met Lys Asn Glu Glu
Glu Val Val Ile Leu Tyr 210 215 220 gcg cag gtg agc gac cgc agc atc
atg cag agt cag agc ctg atg atg 783 Ala Gln Val Ser Asp Arg Ser Ile
Met Gln Ser Gln Ser Leu Met Met 225 230 235 gag ctg cgg gag gag gat
gag gtc tgg gtg cgt ctc ttc aag ggc gag 831 Glu Leu Arg Glu Glu Asp
Glu Val Trp Val Arg Leu Phe Lys Gly Glu 240 245 250 cgt gag aac gcc
att ttc agt gac gag ttc gac acc tac atc acc ttc 879 Arg Glu Asn Ala
Ile Phe Ser Asp Glu Phe Asp Thr Tyr Ile Thr Phe 255 260 265 270 agt
ggc tac ctg gtc aag cca gcc tct gag ccc tagtggacac tcctgtggag 932
Ser Gly Tyr Leu Val Lys Pro Ala Ser Glu Pro 275 280 cttttgtgga
ctgctgacct ccttgcctgg caccctgacc tatccctgca ttctacagac 992
actggagtcc tgccccgggc tgaccccatt ttctctctgc tccatcctgg cttccttggc
1052 cttggcttcc aaagttttgg cttttgacaa gatgcccttg gccactggga
atcccaaagg 1112 atggtgcgat cccagatctg gctgctactc taagcagaga
gctgccggca gatgaaatca 1172 ttgggcgggg agcctgtgag gatattgggg
ggcctccagc tccttctgtg tacacagcct 1232 tagacgaccc tgtgctgtgt
tgtcccgtgg ccacagggtg ttccagagca cagcccctgt 1292 gtgttcccat
tcctggacac aagtaagcaa atatcatggg tttcttagga acgaagtcaa 1352
gcagaaaaga gaaagaaagg tggtgttagt tttggctttc cagccagctg gaaggaggga
1412 tggggagaga gagagagaga gagctatttg tattggggaa actgaggcat
aggaaaaaca 1472 tgaatggcaa cagagtagct gcagtttgtg ggtttggaaa
ccacatctga cttaactcta 1532 gatcacatat gagctttcct ggggacagca
ggactgacct ccgagctctg ttgacatgct 1592 atagccttgc ccaggggctg
gtcaatcttt ctgagccaca ctagtaaaag ggttggagga 1652 gaacagcaag
tgccccctgt ggttggctct gggctggtgg cagcatcctg cttgccccaa 1712
ctcacaggat cctgacagca gctgggaacc tcagggactc ctgcagcttt ctctgtaaga
1772 aataaagctc ctactatgtc ccagtacctc tctgctctgc tccacttccc
cagtcactct 1832 ggaccccagg gtgggagggc tctcttgcct gttgggacat
cagttcccct tcctccttct 1892 tggtgaatta accatggaag gaccagggct
cggatttggg ttcccaaact gcccttcacc 1952 atccctagtg tcctgcttcc
ttcccagttc agcatcctgt ctgggaactt gatactttaa 2012 cctgctagag
cggatgagtc tgatagacct gcccagccct gacacagccc tagtcagctt 2072
atggacacgt gagagggact tcctttgaga cccagagctg gggtagagct ataaaaatct
2132 acctattccc gggtcaaccc caagtggtag aagaggacac aggctatccc
gccctagctc 2192 agactcaggg aaggcctcag gcctgattgt ctgactgcag
agagcctgtg ttctttcccc 2252 atctcacccc gtgttgatcc ccagggcctg
ggccactgga tatctgcttt gtgccaacta 2312 ggccttgctt gctgcttcct
ggtggccctt ggttaggatc cctctctttt ccttctggag 2372 ctcaatgtac
gtatatgcca cctccgaagg ggcttctgct ggtcagactc tccaagccac 2432
ttccatgggt gtgcctacag cagaggctgc tgcctcctgt gctctaccct gctctttcca
2492 gaaaacatta aacttgccat ggcgattcac agcaaaaaaa aaaaaaaaaa
aaaaaaaagg 2552 gcggccg 2559 44 281 PRT Mus musculus 44 Met Gly Ser
Cys Ala Gln Gly Phe Met Leu Gly Cys Cys Leu Leu Leu 1 5 10 15 Ala
Ile Thr Trp Gly Pro Ile Leu Ser Leu Val Pro Arg Val Gln Glu 20 25
30 Glu Gln Gln Glu Trp Glu Glu Thr Glu Glu Leu Pro Ser Pro Leu Asp
35 40 45 Pro Val Thr Arg Pro Glu Glu Thr Arg Glu Lys Tyr Ser Pro
Arg Gln 50 55 60 Gly Glu Asp Leu Pro Thr Ser Arg Cys Tyr Arg Cys
Cys Asp Pro Ser 65 70 75 80 Thr Pro Val Tyr Gln Thr Ile Pro Pro Pro
Gln Ile Asn Ile Thr Ile 85 90 95 Leu Lys Gly Glu Lys Gly Asp Arg
Gly Asp Arg Gly Leu Gln Gly Lys 100 105 110 Tyr Gly Lys Ile Gly Ser
Thr Gly Pro Arg Gly His Val Gly Pro Lys 115 120 125 Gly Gln Lys Gly
Ser Ile Gly Ala Pro Gly Asn His Cys Lys Ser Gln 130 135 140 Tyr Ala
Ala Phe Ser Val Gly Arg Lys Lys Ala Leu His Ser Asn Asp 145 150 155
160 Tyr Phe Gln Pro Val Val Phe Asp Thr Glu Phe Val Asn Leu Tyr Lys
165 170 175 His Phe Asn Met Phe Thr Gly Lys Phe Tyr Cys Tyr Val Pro
Gly Ile 180 185 190 Tyr Phe Phe Ser Leu Asn Val His Thr Trp Asn Gln
Lys Glu Thr Tyr 195 200 205 Leu His Ile Met Lys Asn Glu Glu Glu Val
Val Ile Leu Tyr Ala Gln 210 215 220 Val Ser Asp Arg Ser Ile Met Gln
Ser Gln Ser Leu Met Met Glu Leu 225 230 235 240 Arg Glu Glu Asp Glu
Val Trp Val Arg Leu Phe Lys Gly Glu Arg Glu 245 250 255 Asn Ala Ile
Phe Ser Asp Glu Phe Asp Thr Tyr Ile Thr Phe Ser Gly 260 265 270 Tyr
Leu Val Lys Pro Ala Ser Glu Pro 275 280 45 23 DNA Artificial
Sequence Oligonucleotide ZC23,698 45 gaattcgaat tcctttgttt cca 23
46 43 DNA Artificial Sequence Oligonucleotide ZC23,694 46
taatacgact cactataggg aggaggtacc agggtcacag cag 43 47 20 DNA
Artificial Sequence Oligonucleotide ZC23,703 47 tctacgacca
cttcaacatg 20 48 22 DNA Artificial Sequence Oligonucleotide
ZC23,697 48 gtaattgttt attgtccaga tg 22 49 43 DNA Artificial
Sequence Oligonucleotide ZC24,441 49 atgcattaac cctcactaaa
ggggagaggg ctgaagaaca aca 43 50 41 DNA Artificial Sequence
Oligonucleotide ZC24,442 50 taatacgact cactataggg aggggcggcg
tagtggctct t 41 51 244 PRT Homo sapiens 51 Met Leu Leu Leu Gly Ala
Val Leu Leu Leu Leu Ala Leu Pro Gly His 1 5 10 15 Asp Gln Glu Thr
Thr Thr Gln Gly Pro Gly Val Leu Leu Pro Leu Pro 20 25 30 Lys Gly
Ala Cys Thr Gly Trp Met Ala Gly Ile Pro Gly His Pro Gly 35 40 45
His Asn Gly Ala Pro Gly Arg Asp Gly Arg Asp Gly Thr Pro Gly Glu 50
55 60 Lys Gly Glu Lys Gly Asp Pro Gly Leu Ile Gly Pro Lys Gly Asp
Ile 65 70 75 80 Gly Glu Thr Gly Val Pro Gly Ala Glu Gly Pro Arg Gly
Phe Pro Gly 85 90 95 Ile Gln Gly Arg Lys Gly Glu Pro Gly Glu Gly
Ala Tyr Val Tyr Arg 100 105 110 Ser Ala Phe Ser Val Gly Leu Glu Thr
Tyr Val Thr Ile Pro Asn Met 115 120 125 Pro Ile Arg Phe Thr Lys Ile
Phe Tyr Asn Gln Gln Asn His Tyr Asp 130 135 140 Gly Ser Thr Gly Lys
Phe His Cys Asn Ile Pro Gly Leu Tyr Tyr Phe 145 150 155 160 Ala Tyr
His Ile Thr Val Tyr Met Lys Asp Val Lys Val Ser Leu Phe 165 170 175
Lys Lys Asp Lys Ala Met Leu Phe Thr Tyr Asp Gln Tyr Gln Glu Asn 180
185 190 Asn Val Asp Gln Ala Ser Gly Ser Val Leu Leu His Leu Glu Val
Gly 195 200 205 Asp Gln Val Trp Leu Gln Val Tyr Gly Glu Gly Glu Arg
Asn Gly Leu 210 215 220 Tyr Ala Asp Asn Asp Asn Asp Ser Thr Phe Thr
Gly Phe Leu Leu Tyr 225 230 235 240 His Asp Thr Asn 52 245 PRT Homo
sapiens 52 Met Glu Gly Pro Arg Gly Trp Leu Val Leu Cys Val Leu Ala
Ile Ser 1 5 10 15 Leu Ala Ser Met Val Thr Glu Asp Leu Cys Arg Ala
Pro Asp Gly Lys 20 25 30 Lys Gly Glu Ala Gly Arg Pro Gly Arg Arg
Gly Arg Pro Gly Leu Lys 35 40 45 Gly Glu Gln Gly Glu Pro Gly Ala
Pro Gly Ile Arg Thr Gly Ile Gln 50 55 60 Gly Leu Lys Gly Asp Gln
Gly Glu Pro Gly Pro Ser Gly Asn Pro Gly 65 70 75 80 Lys Val Gly Tyr
Pro Gly Pro Ser Gly Pro Leu Gly Ala Arg Gly Ile 85 90 95 Pro Gly
Ile Lys Gly Thr Lys Gly Ser Pro Gly Asn Ile Lys Asp Gln 100 105 110
Pro Arg Pro Ala Phe Ser Ala Ile Arg Arg Asn Pro Pro Met Gly Gly 115
120 125 Asn Val Val Ile Phe Asp Thr Val Ile Thr Asn Gln Glu Glu Pro
Tyr 130 135 140 Gln Asn His Ser Gly Arg Phe Val Cys Thr Val Pro Gly
Tyr Tyr Tyr 145 150 155 160 Phe Thr Phe Gln Val Leu Ser Gln Trp Glu
Ile Cys Leu Ser Ile Val 165 170 175 Ser Ser Ser Arg Gly Gln Val Arg
Arg Ser Leu Gly Phe Cys Asp Thr 180 185 190 Thr Asn Lys Gly Leu Phe
Gln Val Val Ser Gly Gly Met Val Leu Gln 195 200 205 Leu Gln Gln Gly
Asp Gln Val Trp Val Glu Lys Asp Pro Lys Lys Gly 210 215 220 His Ile
Tyr Gln Gly Ser Glu Ala Asp Ser Val Phe Ser Gly Phe Leu 225 230 235
240 Ile Phe Pro Ser Ala 245 53 215 PRT Tamias sibricus 53 Met Pro
Ala Gln Arg Gly Gly Ala Leu Ser Met Gly Ala Ala Gly Phe 1 5 10 15
Trp Ile Leu Val Leu Ser Ile Thr Ser Ala Leu Ala Asp Ser Asn Asn 20
25 30 Gln Gly Asn Ser Glu Pro Cys Gly Pro Pro Gly Pro Pro Gly Pro
Pro 35 40 45 Gly Ile Pro Gly Phe Pro Gly Ala Pro Gly Ala Leu Gly
Pro Pro Gly 50 55 60 Pro Pro Gly Val Pro Gly Ile Pro Gly Pro Gln
Gly Pro Pro Gly Asp 65 70 75 80 Val Glu Lys Cys Ser Ser Arg Pro Lys
Ser Ala Phe Ala Val Lys Leu 85 90 95 Ser Glu Arg Pro Pro Glu Pro
Phe Gln Pro Ile Val Phe Lys Glu Ala 100 105 110 Leu Tyr Asn Gln Glu
Gly His Phe Asn Met Ala Thr Gly Glu Phe Ser 115 120 125 Cys Val Leu
Pro Gly Val Tyr Asn Phe Gly Phe Asp Ile Arg Leu Phe 130 135 140 Gln
Ser Ser Val Lys Ile Arg Leu Met Arg Asp Gly Ile Gln Val Arg 145 150
155 160 Glu Lys Glu Ala Gln Ala Asn Asp Ser Tyr Lys His Ala Met Gly
Ser 165 170 175 Val Ile Met Ala Leu Gly Lys Gly Asp Lys Val Trp Leu
Glu Ser Lys 180 185 190 Leu Lys Gly Thr Glu Ser Glu Lys Gly Ile Thr
His Ile Val Phe Phe 195 200 205 Gly Tyr Leu Leu Tyr Gly Lys 210 215
54 215 PRT Tamias sibricus 54 Met Tyr Glu Ala Gly Lys Arg Ala Ser
Phe Met Gly Gly Ala Gly Ile 1 5 10 15 Trp Ile Leu Ala Leu Ser Val
Leu Met His Val Val Cys Ser Glu Thr 20 25 30 Gln Gly Asn Pro Glu
Ser Cys Asn Val Pro Gly Pro Gln Gly Pro Pro 35 40 45 Gly Met Arg
Gly Pro Pro Gly Thr Pro Gly Lys Pro Gly Pro Pro Gly 50 55 60 Trp
Asn Gly Phe Pro Gly Leu Pro Gly Pro Pro Gly Pro Pro Gly Met 65 70
75 80 Thr Val Asn Cys His Ser Lys Gly Thr Ser Ala Phe Ala Val Lys
Ala 85 90 95 Asn Glu Leu Pro Pro Ala Pro Ser Gln Pro Val Ile Phe
Lys Glu Ala 100 105 110 Leu His Asp Ala Gln Gly His Phe Asp Leu Ala
Thr Gly Val Phe Thr 115 120 125 Cys Pro Val Pro Gly Leu Tyr Gln Phe
Gly Phe His Ile Glu Ala Val 130 135 140 Gln Arg Ala Val Lys Val Ser
Leu Met Arg Asn Gly Thr Gln Val Met 145 150 155 160 Glu Arg Glu Ala
Glu Ala Gln Asp Gly Tyr Glu His Ile Ser Gly Thr 165 170 175 Ala Ile
Leu Gln Leu Gly Met Glu Asp Arg Val Trp Leu Glu Asn Lys 180 185 190
Leu Ser Gln Thr Asp Leu Glu Arg Gly Thr Val Gln Ala Val Phe Ser 195
200 205 Gly Phe Leu Ile His Glu Asn 210 215 55 224 PRT Rattus
norvegicus 55 Met Pro Ala Pro Gly Arg Gly Pro Arg Gly Pro Leu Leu
Ser Met Pro 1 5 10 15 Gly Arg Arg Gly Ala Leu Arg Glu Pro Ala Asp
Phe Gly Ser Ser Leu 20 25 30 Gly Ala Ala Leu Ala Leu Leu Leu Leu
Leu Leu Pro Ala Cys Cys Pro 35 40 45 Val Lys Ala Gln Asn Asp Thr
Glu Pro Ile Val Leu Glu Gly Lys Cys 50 55 60 Leu Val Val Cys Asp
Ser Ser Pro Ser Gly Asp Gly Ala Val Thr Ser 65 70 75 80 Ser Leu Gly
Ile Ser Val Arg Ser Gly Ser Ala Lys Val Ala Phe Ser 85 90 95 Ala
Thr Arg Ser Thr Asn His Glu Pro Ser Glu Met Ser Asn Arg Thr 100 105
110 Met Thr Ile Tyr Phe Asp Gln Val Leu Val Asn Ile Gly Asn His Phe
115 120 125 Asp Leu Ala Ser Ser Ile Phe Val Ala Pro Arg Lys Gly Ile
Tyr Ser 130 135 140 Phe Ser Phe His Val Val Lys Val Tyr Asn Arg Gln
Thr Ile Gln Val 145 150 155 160 Ser Leu Met Gln Asn Gly Tyr Pro Val
Ile Ser Ala Phe Ala Gly Asp 165 170 175 Gln Asp Val Thr Arg Glu Ala
Ala Ser Asn Gly Val Leu Leu Leu Met 180 185 190 Glu Arg Glu Asp Lys
Val His Leu Lys Leu Glu Arg Gly Asn Leu Met 195 200 205 Gly Gly Trp
Lys Tyr Ser Thr Phe Ser Gly Phe Leu Val Phe Pro Leu 210 215 220
* * * * *